{"chunk_type":"transcript_chunk","text":"**Doorway Thought:** ìˆ˜í˜ˆ ì‹œì‘ í›„ í™˜ìì˜ ë°”ì´íƒˆì´ í”ë“¤ë¦°ë‹¤. \"ì–¸ì œ\" í”ë“¤ë ¸ëŠ”ì§€ì™€ \"ì¦ìƒ\"ì´ ë¬´ì—‡ì¸ì§€ê°€ ë‹µì„ ì•Œë ¤ì¤€ë‹¤.\n| **Reaction** | **Timing** | **Mechanism** | **Key Symptoms** | **Management** |\n| --- | --- | --- | --- | --- |\n| **Anaphylaxis** | **Seconds to Minutes** | IgA Deficiency (Anti-IgA Ab) | Shock, Wheezing, Hypotension | **Stop Transfusion + Epinephrine IM** â˜… |\n| **Acute Hemolytic** | **< 1 Hour** | ABO Incompatibility (Human Error) | **Flank Pain**, Fever, Dark Urine (Hemoglobinuria) | Stop + Hydration (Protect kidneys) |\n| **Febrile Non-Hemolytic** | 1~6 Hours | Cytokines from donor WBCs | Fever, Chills (No pain/hemolysis) | Acetaminophen (Tylenol) + Leukoreduced next time |\n| **Delayed Hemolytic** | Days to Weeks | Anamnestic Response (Memory B cells) | Mild Jaundice, â†“Hb (No acute crash) | Monitor (Usually mild) |\n### **Deep Dive: Delayed Hemolytic Reaction**\n- **Scenario:** ê³¼ê±°ì— ìˆ˜í˜ˆì´ë‚˜ ì„ì‹ ìœ¼ë¡œ Kell, Duffy ê°™ì€ Minor antigenì— ë…¸ì¶œëœ ì ì´ ìˆìŒ. í•­ì²´ ìˆ˜ì¹˜ê°€ ë‚®ì•„ì„œ ìŠ¤í¬ë¦¬ë‹(Negative) í†µê³¼í•¨.\n- **Mechanism:** ë‹¤ì‹œ ìˆ˜í˜ˆë°›ìœ¼ë©´ Memory B-cellì´ ê¹¨ì–´ë‚˜ì„œ(\"Hey, I've seen this before!\") ë©°ì¹  ë’¤ í•­ì²´ë¥¼ ìŸì•„ëƒ„.\n- **Presentation:** ìˆ˜í˜ˆë°›ê³  ì¼ì£¼ì¼ ë’¤ì— í™©ë‹¬(Jaundice)ì´ ì˜¤ê±°ë‚˜ í—¤ëª¨ê¸€ë¡œë¹ˆì´ ìŠ¬ê¸ˆìŠ¬ê¸ˆ ë–¨ì–´ì§.\n---\n# Section 4. Lung Injury: TRALI vs. TACO ğŸ« (High Yield!)\n**Doorway Thought:** 70ì„¸ í• ë¨¸ë‹ˆê°€ ìˆ˜í˜ˆë°›ë‹¤ê°€ ê°‘ìê¸° ìˆ¨ì´ ì°¨ë‹¤(Dyspnea)ê³  í•˜ë©° ì‚°ì†Œí¬í™”ë„ê°€ ë–¨ì–´ì§„ë‹¤. íì²­ì§„ ìƒ Crackle(Wet lungs)ì´ ë“¤ë¦°ë‹¤. ì›ì¸ì€?\n### **The Million Dollar Distinction: Blood Pressure** ğŸ’µ\n### **1. TRALI (Transfusion Related Acute Lung Injury)**\n- **Pathophysiology:** Donorì˜ í•­ì²´(Antibody)ê°€ Recipientì˜ íì— ìˆëŠ” Neutrophilì„ ê³µê²© â†’ **Inflammation** â†’ íí˜ˆê´€ ëˆ„ì¶œ(Leaky capillaries).\n- **Hemodynamics:** í˜ˆê´€ì´ ì¤„ì¤„ ìƒˆë‹ˆê¹Œ í˜ˆì••ì´ **ë–¨ì–´ì§ (Hypotension)** ğŸ“‰.\n- **Treatment:** Supportive Care (Ventilator support). ì´ë‡¨ì œ(Lasix) ì£¼ë©´ ì•ˆ ë¨! (ì´ë¯¸ í˜ˆê´€ ë‚´ ë³¼ë¥¨ì€ ë¶€ì¡±í•  ìˆ˜ ìˆìŒ).\n### **2. TACO (Transfusion Associated Circulatory Overload)**\n- **Pathophysiology:** **Volume Overload**. ì‹¬ë¶€ì „(Heart Failure)ì´ ìˆê±°ë‚˜ ì‹ ë¶€ì „ì´ ìˆëŠ” í™˜ìì—ê²Œ ë„ˆë¬´ ë¹¨ë¦¬/ë§ì´ ìˆ˜í˜ˆí•¨. íŒí”„ê°€ ê°ë‹¹ì„ ëª»í•´ì„œ ë¬¼ì´ íë¡œ ë„˜ì¹¨.\n- **Hemodynamics:** ë¬¼ì´ ê½‰ ì°¼ìœ¼ë‹ˆ í˜ˆì••ì´ **ì˜¤ë¦„ (Hypertension)** ğŸ“ˆ.\n- **Treatment:** **Diuretics (Furosemide)** + Sit up + Oxygen.\n# Section 5. Catheter-Induced Septic Thrombophlebitis ğŸ’‰\n**Doorway Thought:** ì¤‘ì‹¬ì •ë§¥ê´€(Central line)ì„ ê°€ì§„ í™˜ìê°€ ì—´ì´ ë‚˜ì„œ í•­ìƒì œë¥¼ ì¼ëŠ”ë°ë„ 3ì¼ì§¸ ê³ ì—´ì´ ì§€ì†ë¨. ì¹´í…Œí„° ë¶€ìœ„ê°€ ë¹¨ê°›ê³  ì¤„ì„ ë”°ë¼ **ë‹¨ë‹¨í•œ ì¤„(Cord)**ì´ ë§Œì ¸ì§.\n### **Septic Thrombophlebitis (ê°ì—¼ì„± í˜ˆì „ì •ë§¥ì—¼)**\n- **Definition:** ì •ë§¥ ë‚´ì— í˜ˆì „(Thrombus)ì´ ìƒê²¼ëŠ”ë°, ê·¸ í˜ˆì „ì´ ì„¸ê·  ë©ì–´ë¦¬(Abscess/Biofilm)ê°€ ë˜ì–´ë²„ë¦° ìƒíƒœ.\n    - í•­ìƒì œë¥¼ ì¨ë„ í˜ˆì „ ë‚´ë¶€(Bunker)ê¹Œì§€ ì¹¨íˆ¬ë¥¼ ëª»í•¨.\n- **Key Finding:** **Palpable Cord** (í”¼ë¶€ ë°‘ ì •ë§¥ì´ ë¹¨ë˜ì¤„ì²˜ëŸ¼ ë‹¨ë‹¨í•˜ê²Œ ë§Œì ¸ì§) + Persistent Bacteremia.\n- **Bug:** ì£¼ë¡œ **Staphylococcus aureus**.\n- **Management (Step-by-Step):**\n    1. **Pull the Line:** ì›ì¸ ì œê±° (Non-negotiable).\n    2. **Antibiotics:** Vancomycin etc.\n    3. **Anticoagulation:** í˜ˆì „ì´ ë” ì»¤ì§€ëŠ” ê±¸ ë§‰ì•„ì•¼ í•¨.\n    4. **Surgery (Excision):** ë§Œì•½ ìœ„ ì¹˜ë£Œì—ë„ ë°˜ì‘ì´ ì—†ê³ , í˜ˆê´€ì—ì„œ ê³ ë¦„(Pus)ì´ ë‚˜ì˜¤ê±°ë‚˜ íŒ¨í˜ˆì¦ì´ ì§€ì†ë˜ë©´? **í˜ˆê´€ ìì²´ë¥¼ ì˜ë¼ë‚´ì•¼ í•¨ (Excision of the vein)**.\n---","subject":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","page_title":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","episode":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","section_path":["LM_Blood2 2fd46f2986ee8009895af4ea339219a2"],"source_doc_id":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","source_page":null,"source_anchor":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2-386","focus_area":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","tags":["usmle-step2","core","treatment","pathophysiology","mnemonic"]}
{"chunk_type":"recap_summary","text":"### **RAPID FIRE RECAP** âš¡\n| **Scenario** | **Diagnosis** | **Next Best Step** |\n| --- | --- | --- |\n| Gardening + Red Streaks + Hours | **Lymphangitis** | **Cephalexin** (Target Strep) |\n| Transfusion + Anaphylaxis | **IgA Deficiency** | Stop + Epi + Next time **Wash Cells** |\n| Transfusion from Brother | **GVHD Risk** | **Irradiate Blood** (Prevent T-cell attack) |\n| Transfusion + Low BP + Dyspnea | **TRALI** | Supportive Care (Ventilator) |\n| Transfusion + High BP + Dyspnea | **TACO** | **Furosemide** (Diuresis) |\n| Central Line + Palpable Cord | **Septic Thrombophlebitis** | Pull Line + Anticoagulation (+/- Surgery) |\n- **Caveats:** The audio focuses heavily on *Strep pyogenes* for lymphangitis; while true for spontaneous cases, always consider *Pasteurella* (bites) or *Vibrio* (seawater) in real life based on history, though for USMLE, the \"gardening/scratch\" vignette is almost always Strep. For Sporotrichosis, Itraconazole is the Tx, though not explicitly detailed in the audio (audio focused on diagnosis timeline).\n# 7.0-7.5ğŸ“‹ Senior Medical Scribe & USMLE Expert: Lecture Notes\n**Overview (TL;DR)**\nHere is the high-yield summary of the \"Newborn Sludge, Vampire Effect, and Milk Anemia\" lecture:\n- **Neonatal Polycythemia:** \"Tomato Red\" baby due to intrauterine hypoxia or delayed cord clamping. **Trap:** Capillary heel pricks overestimate Hct. **Action:** Confirm with Venous Draw.\n- **Anemia of Prematurity:** Preemies have an \"EPO gap\" because the liver stops and kidneys haven't started. **Vampire Effect:** Iatrogenic blood loss from frequent labs worsens this. **Tx:** Limit blood draws.\n- **Milk Anemia (IDA):** Toddlers drinking >24oz cow's milk. Triple threat: Low iron content, displacement of food, and micro-colitis (bleeding). **Dx:** Mentzer Index > 13.\n- **Pancytopenia:** Bone marrow failure (Aplastic vs. Leukemia). Look at the Spleen size to differentiate production failure vs. destruction/sequestration.\n---","subject":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","page_title":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","episode":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","section_path":["LM_Blood2 2fd46f2986ee8009895af4ea339219a2"],"source_doc_id":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","source_page":null,"source_anchor":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2-405","focus_area":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","tags":["usmle-step2","core","recap","diagnosis","treatment"]}
{"chunk_type":"transcript_chunk","text":"### ğŸŒ³ Top-Down Classification & Structure (ASCII Tree)\nì´ ê°•ì˜ëŠ” Pediatric Hematologyì˜ í•µì‹¬ ë³‘ë¦¬ë“¤ì„ ë‹¤ë£¨ê³  ìˆìŠµë‹ˆë‹¤. ì•„ë˜ êµ¬ì¡°ë„ë¥¼ í†µí•´ í° ê·¸ë¦¼(Big Picture)ì„ ë¨¼ì € ì¡ê³  ë“¤ì–´ê°€ê² ìŠµë‹ˆë‹¤.\nPediatric Hematology (ì†Œì•„ í˜ˆì•¡í•™)\nâ”‚\nâ”œâ”€â”€ Red Blood Cell Disorders (ì í˜ˆêµ¬ ì§ˆí™˜)\nâ”‚   â”‚\nâ”‚   â”œâ”€â”€ Too High (ë„ˆë¬´ ë§ìŒ)\nâ”‚   â”‚   â””â”€â”€ Neonatal Polycythemia (ì‹ ìƒì•„ ë‹¤í˜ˆêµ¬ì¦)\nâ”‚   â”‚       â”œâ”€â”€ Context: \"Tomato Red Baby\" (í† ë§ˆí† ìƒ‰ ì•„ê¸°)\nâ”‚   â”‚       â”œâ”€â”€ Mech: Intrauterine Hypoxia (ìê¶ ë‚´ ì €ì‚°ì†Œ)\nâ”‚   â”‚       â””â”€â”€ Key: Viscosity & Sludge (í˜ˆì•¡ ëˆì ì„)\nâ”‚   â”‚\nâ”‚   â””â”€â”€ Too Low (Anemia, ë¹ˆí˜ˆ)\nâ”‚       â”‚\nâ”‚       â”œâ”€â”€ Production Failure (ìƒì„± ë¶€ì „)\nâ”‚       â”‚   â”œâ”€â”€ Anemia of Prematurity (ë¯¸ìˆ™ì•„ ë¹ˆí˜ˆ)\nâ”‚       â”‚   â”‚   â””â”€â”€ Concept: Hepatic-Renal EPO Gap + Vampire Effect\nâ”‚       â”‚   â”‚","subject":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","page_title":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","episode":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","section_path":["LM_Blood2 2fd46f2986ee8009895af4ea339219a2"],"source_doc_id":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","source_page":null,"source_anchor":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2-415","focus_area":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","tags":["usmle-step2","core","tree"]}
{"chunk_type":"transcript_chunk","text":"â”‚       â”‚   â””â”€â”€ Iron Deficiency Anemia (ì² ê²°í• ë¹ˆí˜ˆ)\nâ”‚       â”‚       â””â”€â”€ Concept: \"Milk Anemia\" (ìš°ìœ  ë¹ˆí˜ˆ, Mentzer Index > 13)\nâ”‚       â”‚\nâ”‚       â””â”€â”€ Destruction / Hemolysis (íŒŒê´´)\nâ”‚           â””â”€â”€ Thalassemia (Mentzer Index < 13)\nâ”‚\nâ””â”€â”€ Pancytopenia (ë²”í˜ˆêµ¬ ê°ì†Œì¦)\nâ”œâ”€â”€ Production Problem: Aplastic Anemia (ë¹ˆ ê³µì¥)\nâ””â”€â”€ Infiltration/Destruction: Leukemia (ì•”ì„¸í¬ ì¹¨ìœ¤) or Hypersplenism (ë¹„ì¥ ë¹„ëŒ€)\n---\n### ğŸ©¸ 1. Neonatal Polycythemia (ì‹ ìƒì•„ ë‹¤í˜ˆêµ¬ì¦)\n**\"The Tomato Red Baby & The Capillary Trap\"**\n### ğŸ©º Clinical Scenario (Vignette)\nì‹ ìƒì•„ì‹¤(Nursery)ì— ìˆëŠ” ì•„ê¸°ê°€ **\"Tomato Red\" (í† ë§ˆí† ì²˜ëŸ¼ ë¶‰ì€ìƒ‰)** í”¼ë¶€ë¥¼ ë³´ì…ë‹ˆë‹¤. ë°œë’¤ê¿ˆì¹˜ë¥¼ ì°”ëŸ¬ì„œ(Heel prick) ì–»ì€ í˜ˆì•¡ ê²€ì‚¬ìƒ **Hematocrit (Hct) 68%** ê°€ ë‚˜ì™”ìŠµë‹ˆë‹¤. ë‹¹ì‹ ì€ íŒ¨ë‹‰ì— ë¹ ì ¸ì•¼ í• ê¹Œìš”?.\n### ğŸ§  Concept & Pathophysiology\n- **Mechanism (Why so red?):** íƒœì•„ëŠ” ìê¶ ë‚´ì—ì„œ ìƒëŒ€ì ì¸ ì €ì‚°ì†Œì¦(Hypoxia) ìƒíƒœì— ìˆìŠµë‹ˆë‹¤. ë§ˆì¹˜ **\"ê³ ì‚°ì§€ëŒ€ì—ì„œ í›ˆë ¨í•˜ëŠ” ë³´ë””ë¹Œë”\"** ì²˜ëŸ¼, ë¶€ì¡±í•œ ì‚°ì†Œë¥¼ ì¡ê¸° ìœ„í•´ ì í˜ˆêµ¬(RBC)ë¥¼ ê³¼ë„í•˜ê²Œ ë§Œë“¤ì–´ëƒ…ë‹ˆë‹¤.\n- **Delayed Cord Clamping:** íƒ¯ì¤„ì„ ëŠ¦ê²Œ ìë¥´ë©´ íƒœë°˜(Placenta)ì— ìˆë˜ í˜ˆì•¡ì´ ì¤‘ë ¥ê³¼ ìˆ˜ì¶•ì— ì˜í•´ ì•„ê¸°ì—ê²Œ ìŸì•„ì ¸ ë“¤ì–´ì˜µë‹ˆë‹¤(Placental Transfusion). ì´ëŠ” \"Free bag of blood\"ë¥¼ ë°›ëŠ” ê²ƒê³¼ ê°™ì•„ í˜ˆì•¡ëŸ‰ì´ ëŠ˜ì–´ë‚©ë‹ˆë‹¤.\n- **Problem (Viscosity):** í˜ˆì•¡ì´ ë„ˆë¬´ ì§„í•´ì§€ë©´ **\"Sludge (ì§„í™/ìŠ¬ëŸ¬ì§€)\"** ì²˜ëŸ¼ ë³€í•©ë‹ˆë‹¤. ëˆì í•œ í”¼ëŠ” ë‡Œ, ì‹ ì¥, ì¥ì˜ ë¯¸ì„¸í˜ˆê´€ì„ í†µê³¼í•˜ì§€ ëª»í•´ ë§‰íˆê²Œ ë©ë‹ˆë‹¤(Stasis).\n### âš ï¸ The Capillary Trap (í•¨ì •)\n- ë°œë’¤ê¿ˆì¹˜(Heel)ì˜ ëª¨ì„¸í˜ˆê´€(Capillaries)ì€ í˜ˆì•¡ ìˆœí™˜ì´ ëŠë¦¬ê³  ì°¨ê°‘ê¸° ë•Œë¬¸ì— í˜ˆì•¡ì´ ê³ ì—¬ìˆìŠµë‹ˆë‹¤(Stasis).\n- ì´ë¡œ ì¸í•´ í˜ˆì¥(Plasma)ì€ ë¹ ì ¸ë‚˜ê°€ê³  ì í˜ˆêµ¬ë§Œ ë†ì¶•ëœ ìƒíƒœì…ë‹ˆë‹¤.\n- **Result:** Heel prick sampleì€ ì‹¤ì œ ì •ë§¥í˜ˆë³´ë‹¤ Hctë¥¼ **ìƒë‹¹íˆ ê³¼ëŒ€í‰ê°€(Overestimate)** í•©ë‹ˆë‹¤.\n### â˜… Management & Next Best Step\n1. **Next Best Step:** **Venous Draw (ì •ë§¥í˜ˆ ì±„í˜ˆ)**.\n    - ì ˆëŒ€ Heel prick ê²°ê³¼ë§Œ ë³´ê³  ì¹˜ë£Œí•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ì •ë§¥ì—ì„œ ë‹¤ì‹œ ë½‘ì•„ì•¼ í•©ë‹ˆë‹¤.\n2. **Diagnosis:** Venous Hematocrit **> 65%**.\n3. **Treatment:**\n    - **Asymptomatic (ì¦ìƒ ì—†ìŒ):** Hydration (ìˆ˜ì•¡ ê³µê¸‰).\n    - **Symptomatic (ì¦ìƒ ìˆìŒ - í˜¸í¡ê³¤ë€, ì²˜ì§ ë“±):** **Partial Exchange Transfusion (ë¶€ë¶„ êµí™˜ ìˆ˜í˜ˆ)**. í”¼ë¥¼ ë½‘ì•„ë‚´ê³  ê·¸ë§Œí¼ ìƒë¦¬ì‹ì—¼ìˆ˜(Normal Saline)ë¥¼ ë„£ì–´ í¬ì„ì‹œí‚µë‹ˆë‹¤.","subject":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","page_title":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","episode":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","section_path":["LM_Blood2 2fd46f2986ee8009895af4ea339219a2"],"source_doc_id":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","source_page":null,"source_anchor":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2-435","focus_area":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","tags":["usmle-step2","core","diagnosis","treatment","pathophysiology"]}
{"chunk_type":"transcript_chunk","text":"---\n### ğŸ§› 2. Anemia of Prematurity (ë¯¸ìˆ™ì•„ ë¹ˆí˜ˆ)\n**\"The Sleeping Foreman & The Vampire Effect\"**\n### ğŸ©º Clinical Scenario (Vignette)\n- **Baby A:** 1ê°œì›” ëœ ë¯¸ìˆ™ì•„(Preemie), ì¸íë² ì´í„°ì— ìˆìŒ. ê°‘ìê¸° ìˆ¨ì„ ì•ˆ ì‰¬ê³ (Apnea), ì‹¬ë°•ìˆ˜ê°€ ë–¨ì–´ì§‘ë‹ˆë‹¤. ë¹ˆí˜ˆì´ ìˆìŠµë‹ˆë‹¤.\n- **Baby B:** 3ê°œì›” ëœ ë§Œì‚­ì•„, ì§‘ì—ì„œ ì˜ ë¨¹ê³  ì›ƒê³  ìˆìŒ. ê²€ì‚¬í•´ë³´ë‹ˆ ë¹ˆí˜ˆ ìˆ˜ì¹˜ê°€ Baby Aì™€ ë¹„ìŠ·í•˜ì§€ë§Œ ì¦ìƒì´ ì—†ìŠµë‹ˆë‹¤.\n- **Why?** Baby AëŠ” \"ê³µì¥\"ì´ ë©ˆì·„ê³ , Baby BëŠ” ì ì‘í•œ ìƒíƒœì…ë‹ˆë‹¤.\n### ğŸ§  Pathophysiology: The EPO Gap\nì í˜ˆêµ¬ ìƒì„± ëª…ë ¹ì„ ë‚´ë¦¬ëŠ” **Erythropoietin (EPO)** ê³µì¥ì˜ ì „í™˜ê¸°ì— ë¬¸ì œê°€ ë°œìƒí•©ë‹ˆë‹¤.\n1. **Fetus (íƒœì•„):** ê°„(Liver)ì´ EPOë¥¼ ë§Œë“­ë‹ˆë‹¤.\n2. **Adult (ì„±ì¸):** ì‹ ì¥(Kidney)ì´ EPOë¥¼ ë§Œë“­ë‹ˆë‹¤.\n3. **The Gap:** íƒœì–´ë‚˜ë©´ ê°„ì€ \"ë‚´ í•  ì¼ ëë‚¬ë‹¤\"ë©° ì€í‡´í•©ë‹ˆë‹¤. í•˜ì§€ë§Œ ë¯¸ìˆ™ì•„ì˜ ì‹ ì¥ì€ ì•„ì§ ë¯¸ì„±ìˆ™í•´ì„œ \"ì ìê³  ìˆëŠ” ê³µì¥ì¥(Sleeping Foreman)\"ê³¼ ê°™ìŠµë‹ˆë‹¤.\n    - ëª…ë ¹(EPO)ì´ ì—†ìœ¼ë‹ˆ ê³¨ìˆ˜(Bone Marrow)ëŠ” ì¼ì„ ì•ˆ í•©ë‹ˆë‹¤.\n### ğŸ©¸ The Vampire Effect (í¡í˜ˆê·€ íš¨ê³¼)\n- ë¯¸ìˆ™ì•„ëŠ” ë§¤ì¼ ìˆ˜ë§ì€ í˜ˆì•¡ ê²€ì‚¬ë¥¼ ë°›ìŠµë‹ˆë‹¤.\n- 1kg ë¯¸ë§Œì˜ ë¯¸ìˆ™ì•„ì—ê²Œì„œ **5ml**ì˜ í”¼ë¥¼ ë½‘ëŠ” ê²ƒì€, ì„±ì¸ì´ ì ì‹­ìì— ê°€ì„œ **í”¼ í•œ íŒ©(Pint)**ì„ ê¸°ë¶€í•˜ëŠ” ê²ƒê³¼ ë§ë¨¹ëŠ” ë¹„ìœ¨ì…ë‹ˆë‹¤.\n- ì´ê±¸ 3ì¼ ì—°ì†í•˜ë©´? ì•„ê¸°ì˜ í”¼ë¥¼ ì˜ë£Œì§„ì´ ë‹¤ ë½‘ì•„ë²„ë¦° ì…ˆì…ë‹ˆë‹¤ (**Iatrogenic Blood Loss**).\n### â˜… Treatment & Gold Standard\n- **Gold Standard:** **Restraint (ìì œë ¥/ì°¸ê¸°)**.\n    - ë¶ˆí•„ìš”í•œ í˜ˆì•¡ ê²€ì‚¬ë¥¼ ë©ˆì¶”ëŠ” ê²ƒì´ ìµœê³ ì˜ ì¹˜ë£Œì…ë‹ˆë‹¤.\n    - \"Doing nothing is actually doing something.\" (ì•„ë¬´ê²ƒë„ ì•ˆ í•˜ëŠ” ê²ƒì´ ì¹˜ë£Œë‹¤).\n- ì¦ìƒì´ ì‹¬ê°í•˜ë©´(Apnea, Bradycardia ë“±) ìˆ˜í˜ˆì„ ê³ ë ¤í•˜ì§€ë§Œ, ê¸°ë³¸ì€ ê¸°ë‹¤ë¦¬ëŠ” ê²ƒì…ë‹ˆë‹¤.\n---\n### ğŸ¥› 3. Milk Anemia (ìš°ìœ  ë¹ˆí˜ˆ - Iron Deficiency)\n**\"The Milkatiarian & The Triple Threat\"**\n### ğŸ©º Clinical Scenario (Vignette)\n15ê°œì›” ëœ ë‚¨ìì•„ì´. ë°¥(ì¹˜í‚¨, ë¸Œë¡œì½œë¦¬)ì€ ì•ˆ ë¨¹ê³  **ìš°ìœ ë³‘ë§Œ í•˜ë£¨ ì¢…ì¼** ë¹¨ê³  ìˆìŠµë‹ˆë‹¤(í•˜ë£¨ 30oz ì´ìƒ). ì•„ì´ê°€ ì°½ë°±í•˜ê³ (Pale), ì§œì¦ì„ ì˜ ëƒ…ë‹ˆë‹¤(Irritable). í™ì´ë‚˜ ì–¼ìŒì„ ì”¹ì–´ë¨¹ìœ¼ë ¤ í•©ë‹ˆë‹¤(Pica).\n### ğŸ§  Pathophysiology: The Triple Threat\nìš°ìœ (Cow's milk)ëŠ” ë¹ˆí˜ˆì„ ì¼ìœ¼í‚¤ëŠ” 3ê°€ì§€ ê¸°ì „ì„ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤.\n1. **Low Iron:** ìš°ìœ  ìì²´ì— ì² ë¶„ì´ ê±°ì˜ ì—†ìŠµë‹ˆë‹¤ (Zero raw material).\n2. **Displacement:** ìš°ìœ ëŠ” ì¹¼ë¡œë¦¬ê°€ ë†’ê³  ë°°ê°€ ë¶€ë¦…ë‹ˆë‹¤. ì•„ì´ê°€ ìš°ìœ ë¡œ ë°°ë¥¼ ì±„ìš°ë‹ˆ ì² ë¶„ì´ ë“  ì´ìœ ì‹(ê³ ê¸°, ì‹œë¦¬ì–¼ ë“±)ì„ ì•ˆ ë¨¹ìŠµë‹ˆë‹¤.\n3. **Micro-Colitis:** ìš°ìœ  ë‹¨ë°±ì§ˆì´ ì¥ ì ë§‰ì„ ìê·¹í•´ ë¯¸ì„¸í•œ ì¶œí˜ˆ(**Microscopic Colitis**)ì„ ì¼ìœ¼í‚µë‹ˆë‹¤. ë§¤ì¼ ì¡°ê¸ˆì”© í”¼(ì™€ ì² ë¶„)ê°€ ëŒ€ë³€ìœ¼ë¡œ ë¹ ì ¸ë‚˜ê°‘ë‹ˆë‹¤.","subject":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","page_title":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","episode":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","section_path":["LM_Blood2 2fd46f2986ee8009895af4ea339219a2"],"source_doc_id":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","source_page":null,"source_anchor":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2-455","focus_area":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","tags":["usmle-step2","core","treatment","pathophysiology"]}
{"chunk_type":"transcript_chunk","text":"### ğŸ“Š Diagnosis: The Mentzer Index\nMCV(ì í˜ˆêµ¬ í¬ê¸°)ê°€ ì‘ì„ ë•Œ, ì´ê²ƒì´ ì² ê²°í•ì¸ì§€ Thalassemia(ìœ ì „ë³‘)ì¸ì§€ êµ¬ë³„í•˜ëŠ” ìˆ˜í•™ì  ê¿€íŒì…ë‹ˆë‹¤.\n$$\\text{Mentzer Index} = \\frac{\\text{MCV}}{\\text{RBC Count}}$$\n| **Condition** | **Mentzer Index** | **Mechanism** |\n| --- | --- | --- |\n| **Iron Deficiency** | **> 13** | ê³¨ìˆ˜ê°€ ì¬ë£Œ(ì² )ê°€ ì—†ì–´ ì„¸í¬ë¥¼ **ì ê²Œ** ë§Œë“¦ (RBC â†“) â†’ ë¶„ëª¨ê°€ ì‘ì•„ì ¸ì„œ ê°’ ìƒìŠ¹ |\n| **Thalassemia** | **< 13** | ê³µì¥ì€ ì •ìƒì´ì§€ë§Œ ë¶ˆëŸ‰í’ˆì„ **ë§ì´** ì°ì–´ëƒ„ (RBC â†‘) â†’ ë¶„ëª¨ê°€ ì»¤ì ¸ì„œ ê°’ í•˜ë½ |\n- **Pica (ì´ì‹ì¦):** í™, ì í† , ì¢…ì´ ë“±ì„ ë¨¹ìŒ.\n- **Pagophagia:** ì–¼ìŒì„ ê°•ë°•ì ìœ¼ë¡œ ì”¹ì–´ ë¨¹ìŒ (Ice craving).\n### â˜… Management\n- **Strict Limit:** ìš°ìœ  ì„­ì·¨ë¥¼ í•˜ë£¨ **24oz (ì•½ 700ml) ë¯¸ë§Œ**ìœ¼ë¡œ ì œí•œí•©ë‹ˆë‹¤.\n- ì² ë¶„ ë³´ì¶©ì œë¥¼ íˆ¬ì—¬í•©ë‹ˆë‹¤.\n---\n### ğŸ“‰ 4. Pancytopenia (ë²”í˜ˆêµ¬ ê°ì†Œì¦)\n**\"Production vs. Destruction\"**\n### ğŸ©º Clinical Scenario (Vignette)\nì•„ì´ê°€ ë©ì´ ì˜ ë“¤ê³ (Bruising), ì—´ì´ ë‚˜ë©°(Fever), ì°½ë°±í•©ë‹ˆë‹¤. CBC ê²€ì‚¬ìƒ ì í˜ˆêµ¬, ë°±í˜ˆêµ¬, í˜ˆì†ŒíŒì´ ëª¨ë‘ ë‚®ìŠµë‹ˆë‹¤(**Pancytopenia**). ì–´ë””ì„œë¶€í„° ì‹œì‘í•´ì•¼ í• ê¹Œìš”?\n### ğŸ§  Clinical Logic: Factory vs. Bouncer\nì›ì¸ì€ í¬ê²Œ ë‘ ê°€ì§€ì…ë‹ˆë‹¤.\n1. **Production Failure (ê³µì¥ì´ ë§í•¨):**\n    - **Aplastic Anemia (ì¬ìƒë¶ˆëŸ‰ì„± ë¹ˆí˜ˆ):** ê³¨ìˆ˜ ìƒê²€(Biopsy)ì„ í•˜ë©´ ì„¸í¬ê°€ ì—†ê³  ì§€ë°©(Fat)ë§Œ ê°€ë“í•©ë‹ˆë‹¤ (**Empty Factory**).\n    - ì›ì¸: ë°”ì´ëŸ¬ìŠ¤, ì•½ë¬¼, í˜¹ì€ ìœ ì „(Fanconi Anemia).\n    - **Fanconi Anemia:** í‚¤ê°€ ì‘ê³ , ì—„ì§€ì†ê°€ë½ ê¸°í˜•(Thumb abnormalities), ì¹´í˜ì˜¤ë ˆ ë°˜ì (CafÃ©-au-lait spots).\n2. **Destruction / Infiltration (ê³µì¥ì€ ë¶ë¹„ëŠ”ë° ë¬¼ê±´ì´ ì•ˆ ë‚˜ì˜´):**\n    - **Leukemia (ë°±í˜ˆë³‘):** ì•”ì„¸í¬(Blast)ê°€ ê³¨ìˆ˜ë¥¼ ê°€ë“ ì±„ì›Œ ì •ìƒ ì„¸í¬ê°€ ìë„ ê³µê°„ì´ ì—†ìŠµë‹ˆë‹¤ (Weeds choking the garden).\n    - **Hypersplenism (ë¹„ì¥ê¸°ëŠ¥í•­ì§„):** ë¹„ì¥ì´ ë„ˆë¬´ ì»¤ì ¸ì„œ í˜ˆêµ¬ë“¤ì„ ë‹¤ ì¡ì•„ê°€ë‘¡ë‹ˆë‹¤.\n### â˜… Physical Exam Key\n- **Spleen Size (ë¹„ì¥ í¬ê¸°):** ë¹„ì¥ì´ ë§Œê²¨ì§€ë‚˜ìš”?\n    - **Splenomegaly (+):** íŒŒê´´(Destruction)ë‚˜ ì¹¨ìœ¤(Infiltration/Leukemia)ì„ ì˜ì‹¬. ë¹„ì¥ì€ í˜ˆêµ¬ë“¤ì„ ê°€ë‘ëŠ” **\"Bouncer(ê¸°ë„)\"** ì—­í• ì„ í•©ë‹ˆë‹¤.\n    - **No Splenomegaly:** ìƒì‚° ë¶€ì „(Aplastic anemia)ì„ ì˜ì‹¬.\n---","subject":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","page_title":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","episode":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","section_path":["LM_Blood2 2fd46f2986ee8009895af4ea339219a2"],"source_doc_id":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","source_page":null,"source_anchor":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2-475","focus_area":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","tags":["usmle-step2","core","diagnosis","treatment","pathophysiology"]}
{"chunk_type":"recap_summary","text":"### ğŸ”¥ Rapid Fire Recap: The 3 Magic Numbers\nê°•ì˜ì—ì„œ ê°•ì¡°í•œ **ë°˜ë“œì‹œ ì™¸ì›Œì•¼ í•  3ê°€ì§€ ìˆ«ì**ì…ë‹ˆë‹¤.\n| **Number** | **Context** | **Meaning** |\n| --- | --- | --- |\n| **65%** | Neonatal Polycythemia | **Venous** Hematocritê°€ ì´ ì´ìƒì´ì–´ì•¼ ì§„ë‹¨ë¨ (Heel prick X). |\n| **24 oz** | Milk Anemia | ìœ ì•„ì˜ ìš°ìœ  ì„­ì·¨ ì œí•œëŸ‰ (ì´ë³´ë‹¤ ë§ì´ ë§ˆì‹œë©´ ì² ê²°í• ìœ„í—˜). |\n| **13** | Mentzer Index | MCV/RBC. **>13**ì´ë©´ Iron Deficiency, **<13**ì´ë©´ Thalassemia. |\n**Final Caveat:** ì´ ë‚´ìš©ì€ êµìœ¡ìš©ì´ë©°, ì‹¤ì œ ì•„í”ˆ ì•„ì´ ì•ì—ì„œëŠ” íŒŸìºìŠ¤íŠ¸ê°€ ì•„ë‹ˆë¼ **ë³‘ì› í”„ë¡œí† ì½œ(Hospital Protocol)**ì„ ë”°ë¥´ì„¸ìš”!.","subject":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","page_title":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","episode":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","section_path":["LM_Blood2 2fd46f2986ee8009895af4ea339219a2"],"source_doc_id":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","source_page":null,"source_anchor":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2-492","focus_area":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","tags":["usmle-step2","core","recap"]}
{"chunk_type":"transcript_chunk","text":"# LM_OSRHM\n**Part 1: ê´€ì ˆì—¼ê³¼ ë¥˜ë§ˆí‹°ìŠ¤ (The Arthritic Patient)**\nê°€ì¥ í”í•˜ê³  ë°©ëŒ€í•œ ì£¼ì œì¸ ê´€ì ˆí†µì„ ê¸°ì „ë³„ë¡œ ë‚˜ëˆ„ì–´ ì •ë¦¬í•©ë‹ˆë‹¤.\n**Episode 1. ë¹„ì—¼ì¦ì„± ê´€ì ˆí†µê³¼ ê¸‰ì„± ë‹¨ê´€ì ˆì—¼ (Mechanical & Crystal)**\n- **ì£¼ì œ:**Â \"ë¬´ë¦ì´ ì‘¤ì…”ìš”(OA)\" vs \"ì—„ì§€ë°œê°€ë½ì´ ë¶ˆíƒ€ìš”(Gout/Septic)\".\n- **ë‚´ìš©:**Â ê³¨ê´€ì ˆì—¼ì˜ ê¸°ì „ê³¼ íŠ¹ì§•, í†µí’ê³¼ ê°€ì§œí†µí’ì˜ ê°ë³„, ê·¸ë¦¬ê³  ì‘ê¸‰ì¸ ê°ì—¼ì„± ê´€ì ˆì—¼(Septic Arthritis)ê³¼ ì„ì§ˆê·  ê°ì—¼. ì¶”ê°€ë¡œ ê¸°ê³„ì  ë¬¸ì œì¸ í„±ê´€ì ˆ(TMJ)ì„ í•¨ê»˜ ë‹¤ë£¹ë‹ˆë‹¤.\n- **Covered TOC Sections:**\n    - 1.1 Osteoarthritis\n    - 1.5 Septic Arthritis\n    - 1.6 Disseminated Gonococcal Infection\n    - 1.8 Gout\n    - 2.0 Temporomandibular Joint\n**Episode 2. ì „ì‹  ìê°€ë©´ì—­ ì§ˆí™˜ I (Systemic Autoimmune - RA & SLE)**\n- **ì£¼ì œ:**Â \"ì˜¨ëª¸ì˜ ê´€ì ˆì´ ì•„í”„ê³  í”¼ê³¤í•´ìš”\".\n- **ë‚´ìš©:**Â ë¥˜ë§ˆí‹°ìŠ¤ ê´€ì ˆì—¼(RA)ì˜ ì§„ë‹¨ê³¼ ì•½ë¬¼(Methotrexate ë¶€ì‘ìš©), í í‹° ì¦í›„êµ°. ì „ì‹  í™ë°˜ì„± ë£¨í‘¸ìŠ¤(SLE)ì˜ ë‹¤ì–‘í•œ ì„ìƒ ì–‘ìƒ(ì‹ ì¥, í”¼ë¶€) ë° í•­ì¸ì§€ì§ˆ ì¦í›„êµ°(APLA).\n- **Covered TOC Sections:**\n    - 1.2 Rheumatoid Arthritis\n    - 1.3 Felty Syndrome\n    - 1.9 SLE (Systemic Lupus Erythematosus)\n    - 1.10 APLA (Antiphospholipid Syndrome)\n    - 1.11 Mixed Connective Tissue Disorder\n**Episode 3.** ì „ì‹  ìê°€ë©´ì—­ ì§ˆí™˜ II (Spondylo & Connective Tissue)\n- ì£¼ì œ: \"í—ˆë¦¬ê°€ ë»£ë»£í•´ìš”\" & \"ëˆˆê³¼ ì…ì´ ë§ë¼ìš”\".\n- ë‚´ìš©: ê°•ì§ì„± ì²™ì¶”ì—¼ ë“± í˜ˆì²­ìŒì„± ì²™ì¶”ê´€ì ˆë³‘ì¦(Seronegative), ì‡¼ê·¸ë Œ ì¦í›„êµ°(ê±´ì¡°ì¦), ê²½í”¼ì¦(Scleroderma)ê³¼ ë ˆì´ë…¸ í˜„ìƒ.\n- Covered TOC Sections:\n    - 1.7 Seronegative Spondyloarthritis\n    - 1.12 Sjogren Syndrome\n    - 1.13 Scleroderma\n    - 10.2 Raynaudâ€™s Phenomenon (ë ˆì´ë…¸ëŠ” ê²½í”¼ì¦/í˜ˆê´€ì—¼ ë§¥ë½ì—ì„œ ë‹¤ë£¨ëŠ” ê²ƒì´ íš¨ìœ¨ì ì…ë‹ˆë‹¤)\n---\n**Part 2: êµ­ì†Œ í†µì¦ê³¼ ìŠ¤í¬ì¸  ì˜í•™ (Regional Pain & Sports Med)**\n\"ì–´ë””ê°€ ì•„í”ˆì§€\"ì— ë”°ë¼ í•´ë¶€í•™ì ìœ¼ë¡œ ì ‘ê·¼í•©ë‹ˆë‹¤.\n**Episode 4. ìƒì§€ í†µì¦ I: ì–´ê¹¨ì™€ íŒ”ê¿ˆì¹˜ (Shoulder & Elbow)**\n- **ì£¼ì œ:**Â \"íŒ”ì„ ëª» ë“¤ê² ì–´ìš”\".\n- **ë‚´ìš©:**Â íšŒì „ê·¼ê°œ íŒŒì—´ vs ì˜¤ì‹­ê²¬(ìœ ì°©ì„± ê´€ì ˆë‚­ì—¼) ê°ë³„, ì–´ê¹¨ íƒˆêµ¬, ìƒê²¬ê°‘ ì‹ ê²½ í¬ì°©. íŒ”ê¿ˆì¹˜ í†µì¦(í…Œë‹ˆìŠ¤ ì—˜ë³´)ê³¼ ì£¼ë‘ ì ì•¡ë‚­ì—¼(Olecranon bursitis).\n- **Covered TOC Sections:**\n    - 3.2 Shoulder (3.2.1 Adhesive Capsulitis ~ 3.2.4 Suprascapular Nerve Entrapment)\n    - 3.4 Elbow\n    - 8.1 Olecranon Bursitis\n**Episode 5. ìƒì§€ í†µì¦ II: ì†ëª©ê³¼ ì† (Hand & Wrist)**\n- **ì£¼ì œ:**Â \"ì†ëª©ì´ ì €ë¦¬ê³  í˜¹ì´ ë‚¬ì–´ìš”\".\n- **ë‚´ìš©:**Â ì†ëª©í„°ë„ì¦í›„êµ°, ë“œí€˜ë¥´ë±… í˜ì¤„ìœ¤í™œì—¼, ë“€í”¼íŠ¸ë Œ êµ¬ì¶•, ê²°ì ˆì¢…(Ganglion Cyst).\n- **Covered TOC Sections:**\n    - 3.1 Carpal Tunnel\n    - 3.3 De Quervain Tendinopathy\n    - 3.5 Dupuytren Contractures\n    - 13.8 Ganglion Cyst\n**Episode 6. ì²™ì¶” ì§ˆí™˜ (The Spine)**\n- **ì£¼ì œ:**Â \"í—ˆë¦¬ì™€ ëª©ì´ ì•„íŒŒì„œ ë‹¤ë¦¬ê°€ ì €ë ¤ìš”\".\n- **ë‚´ìš©:**Â ì²™ì¶”ê´€ í˜‘ì°©ì¦(Neurogenic claudication), ë””ìŠ¤í¬(Radiculopathy), ì „ë°©ì „ìœ„ì¦, ì²™ì¶” ì™¸ìƒ ë° ì••ë°• ê³¨ì ˆ.\n- **Covered TOC Sections:**\n    - 5.0 Spine ì „ì²´ (5.1 Spondylosis ~ 5.9 Spine Trauma)\n**Episode 7. í•˜ì§€ í†µì¦ I: ê³ ê´€ì ˆê³¼ ë¬´ë¦ (Hip & Knee)**\n- **ì£¼ì œ:**Â \"ë¬´ë¦ì—ì„œ ì†Œë¦¬ê°€ ë‚˜ìš”\".\n- **ë‚´ìš©:**Â ì‹­ìì¸ëŒ€(ACL/PCL) ë° ë°˜ì›”ìƒ ì—°ê³¨ ì†ìƒ, ìŠ¬ê°œëŒ€í‡´ í†µì¦ ì¦í›„êµ°(Runner's knee), ë² ì´ì»¤ ë‚­ì¢…, ê³ ê´€ì ˆ ì ì•¡ë‚­ì—¼.\n- **Covered TOC Sections:**\n    - 4.1 Trochanteric Bursitis\n    - 4.2 Knee ì „ì²´ (4.2.1 Rupture ~ 4.2.7 Meniscal Tear)\n    - 8.2 Pes Anserine Bursitis","subject":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","page_title":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","episode":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","section_path":["LM_OSRHM 30046f2986ee8098921dc4e04b63ee22"],"source_doc_id":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","source_page":null,"source_anchor":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22-1","focus_area":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","tags":["usmle-step2","core","pathophysiology"]}
{"chunk_type":"transcript_chunk","text":"**Episode 8. í•˜ì§€ í†µì¦ II: ë°œê³¼ ë°œëª© (Foot & Ankle)**\n- **ì£¼ì œ:**Â \"ì•„ì¹¨ì— ì²« ë°œ ë””ë”œ ë•Œ ì•„íŒŒìš”\".\n- **ë‚´ìš©:**Â ì¡±ì €ê·¼ë§‰ì—¼, ì•„í‚¬ë ˆìŠ¤ ê±´ì—¼, ë°œëª© ì—¼ì¢Œ(Ottawa Rules), ìƒ¤ë¥´ì½” ê´€ì ˆ(ë‹¹ë‡¨ë°œ).\n- **Covered TOC Sections:**\n    - 4.3 Ankle & Foot ì „ì²´ (4.3.1 Plantar ~ 4.3.3 Calcaneal Apophysitis)\n    - 13.3 Charcot Joint\n---\n**Part 3: ë¼ˆ ë³‘ë¦¬, ì™¸ìƒ, ì†Œì•„ (Pathology, Trauma, Peds)**\níŠ¹ì • ì§ˆí™˜êµ°ê³¼ ì†Œì•„ê³¼ ë‚´ìš©ì„ ë¬¶ì—ˆìŠµë‹ˆë‹¤.\n**Episode 9. ì™¸ìƒê³¼ ê³¨ì ˆ í•©ë³‘ì¦ (Trauma & Complications)**\n- **ì£¼ì œ:**Â \"ë„˜ì–´ì§„ í›„ ë¼ˆê°€ ë¶€ëŸ¬ì¡Œì–´ìš”\".\n- **ë‚´ìš©:**Â ì£¼ìš” ê³¨ì ˆ(ëŒ€í‡´ê³¨, ì†ëª©, ì‡„ê³¨), ì†Œì•„ ê³¨ì ˆ(Supracondylar, Greenstick), ê·¸ë¦¬ê³  ê³¨ì ˆ í•©ë³‘ì¦ì¸ êµ¬íš ì¦í›„êµ°, CRPS, ì§€ë°©ìƒ‰ì „ì¦ ë“±.\n- **Covered TOC Sections:**\n    - 7.0 Fracture ì „ì²´ (7.1 Femur ~ 7.8 Pelvic)\n    - 13.2 Compartment Syndrome\n    - 13.4 Complex Regional Pain Syndrome (CRPS)\n    - 13.5 Amputation\n    - 13.7 Myositis Ossificans (ì™¸ìƒ í›„ ë°œìƒ)\n**Episode 10. ë¼ˆì˜ ë³‘ë¦¬ì™€ ì¢…ì–‘ (Bone Pathology & Tumors)**\n- **ì£¼ì œ:**Â \"ë¼ˆê°€ ì•½í•´ì§€ê±°ë‚˜ í˜¹ì´ ìƒê²¼ì–´ìš”\".\n- **ë‚´ìš©:**Â ê³¨ë‹¤ê³µì¦ê³¼ ì•½ë¬¼(Bisphosphonate), ê³¨ìˆ˜ì—¼(Osteomyelitis), ë¬´í˜ˆì„± ê´´ì‚¬(AVN), ê³¨ì¢…ì–‘(Osteosarcoma, Ewing's ë“±). ì¸ê³µê´€ì ˆ ê°ì—¼ë„ ë¼ˆ ê°ì—¼ ë§¥ë½ì—ì„œ í•¨ê»˜ ë‹¤ë£¹ë‹ˆë‹¤.\n- **Covered TOC Sections:**\n    - 6.0 Bone Pathology ì „ì²´ (6.1 AVN ~ 6.5 Osteomyelitis)\n    - 11.1 Bisphosphonate Osteonecrosis\n    - 12.0 Tumors ì „ì²´ (12.1 ~ 12.3)\n    - 13.1 Prosthetic Joint\n    - 13.6 Langerhans Histiocytosis\n**Episode 11. í˜ˆê´€ì—¼ê³¼ ê·¼ìœ¡ë³‘ì¦ (Vasculitis & Myopathy)**\n- **ì£¼ì œ:**Â \"í˜ˆê´€ì— ì—¼ì¦ì´ ìˆê±°ë‚˜ ê·¼ìœ¡ì— í˜ì´ ì—†ì–´ìš”\".\n- **ë‚´ìš©:**Â í˜ˆê´€ì—¼(GCA, Takayasu, Kawasaki, Henoch-Schonlein ë“±), ê·¼ìœ¡ë³‘ì¦(Polymyositis, Dermatomyositis), ì¤‘ì¦ê·¼ë¬´ë ¥ì¦(Myasthenia Gravis).\n- **Covered TOC Sections:**\n    - 9.0 Vasculitis ì „ì²´ (9.1 ~ 9.3)\n    - 10.1 Myasthenia Gravis\n    - *Note:*Â ì†ŒìŠ¤ì˜ 10.0 MyopathyëŠ”ì—ì„œ ì—¼ì¦ì„± ê·¼ìœ¡ë³‘ì¦(Polymyositis ë“±)ì„ í¬í•¨í•˜ê³  ìˆìœ¼ë¯€ë¡œ ì´ ì—í”¼ì†Œë“œì—ì„œ ë‹¤ë£¹ë‹ˆë‹¤.\n**Episode 12. ì†Œì•„ ì •í˜•ì™¸ê³¼ (Pediatric Orthopedics)**\n- **ì£¼ì œ:**Â \"ì•„ì´ê°€ ë‹¤ë¦¬ë¥¼ ì ˆì–´ìš” (The Limping Child)\".\n- **ë‚´ìš©:**Â ë°œë‹¬ì„± ê³ ê´€ì ˆ ì´í˜•ì„±ì¦(DDH), LCPë³‘, SCFE ë“± ì†Œì•„ ê³ ê´€ì ˆ ì§ˆí™˜. ì†Œì•„ ë¥˜ë§ˆí‹°ìŠ¤(JIA). ì„±ì¥í†µ, ì•ˆì§±ë‹¤ë¦¬, ì²™ì¶”ì¸¡ë§Œì¦.\n- **Covered TOC Sections:**\n    - 1.4 Juvenile Idiopathic Arthritis (JIA)\n    - 14.0 Peads Musculocutaneous ì „ì²´ (14.1 Genu Varum ~ 14.11 Strength Training)\n---\n### ğŸ“ Overview (TL;DR)\nì´ë²ˆ Deep DiveëŠ” **Joint Pain (ê´€ì ˆí†µ)**ì— ëŒ€í•œ ì´ì •ë¦¬ì…ë‹ˆë‹¤. ë‹¨ìˆœí•œ í†µì¦ ê´€ë¦¬ê°€ ì•„ë‹ˆë¼, **\"ë†“ì¹˜ë©´ í°ì¼ ë‚˜ëŠ” ì‘ê¸‰ ì§ˆí™˜(Septic Arthritis)\"**ë¶€í„° **\"ì‚¶ì˜ ì§ˆì„ ë–¨ì–´ëœ¨ë¦¬ëŠ” ë§Œì„± ì§ˆí™˜(OA)\"**ê¹Œì§€, ê·¸ë¦¬ê³  **\"íƒì •ì²˜ëŸ¼ ì°¾ì•„ë‚´ì•¼ í•˜ëŠ” ì „ì‹  ì§ˆí™˜(Vasculitis, DGI)\"**ê¹Œì§€ í­ë„“ê²Œ ë‹¤ë£¹ë‹ˆë‹¤.\n- **í•µì‹¬ ì£¼ì œ:** Septic Arthritis vs Gout vs OA vs RA vs Spondyloarthropathies\n- **Key Skills:** ê´€ì ˆì•¡ ë¶„ì„(Synovial Fluid Analysis) í•´ì„ ëŠ¥ë ¥, \"Doorway Diagnosis\" (í™˜ì ë³´ìë§ˆì ì§„ë‹¨í•˜ê¸°).\n- **Must-Know:** Kocher Criteria (ì†Œì•„), Fight Bite ê´€ë¦¬ë²•, Gonorrhea Triad, OAì˜ ë‹¨ê³„ë³„ ì¹˜ë£Œ.\n---","subject":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","page_title":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","episode":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","section_path":["LM_OSRHM 30046f2986ee8098921dc4e04b63ee22"],"source_doc_id":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","source_page":null,"source_anchor":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22-21","focus_area":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","tags":["usmle-step2","core","diagnosis","treatment"]}
{"chunk_type":"transcript_chunk","text":"---\n### ğŸŒ³ Top-down Classification: Joint Pain\nì´ ê°•ì˜ëŠ” **Joint Pain**ì´ë¼ëŠ” ê±°ëŒ€í•œ ìˆ²ì—ì„œ ì‹œì‘í•˜ì—¬, ì—¼ì¦ì„±(Inflammatory)ì¸ì§€ ë¹„ì—¼ì¦ì„±(Non-inflammatory)ì¸ì§€, ê·¸ë¦¬ê³  ë‹¨ê´€ì ˆ(Mono)ì¸ì§€ ë‹¤ê´€ì ˆ(Poly)ì¸ì§€ë¥¼ êµ¬ë¶„í•´ ë‚˜ê°€ëŠ” ê³¼ì •ì…ë‹ˆë‹¤.\nPlaintext\n`JOINT PAIN (The Big Picture)\nâ”‚\nâ”œâ”€â”€ Monoarthritis (ë‹¨ê´€ì ˆì—¼: 1 Joint, Red, Hot, Swollen)\nâ”‚   â”œâ”€â”€ EMERGENCY (ë†“ì¹˜ë©´ ê´€ì ˆ íŒŒê´´/ì‚¬ë§)\nâ”‚   â”‚   â””â”€â”€ Septic Arthritis (Infection) ğŸš¨\nâ”‚   â”‚       â”œâ”€â”€ Adult: Staph aureus (MC)\nâ”‚   â”‚       â”œâ”€â”€ Young/Sexually Active: N. gonorrhoeae (DGI)\nâ”‚   â”‚       â””â”€â”€ Pediatric: Hip/Knee (Kocher Criteria)\nâ”‚   â”‚\nâ”‚   â”œâ”€â”€ Crystal Arthropathies (Inflammatory)\nâ”‚   â”‚   â”œâ”€â”€ Gout (MSU crystals)\nâ”‚   â”‚   â””â”€â”€ Pseudogout (CPPD crystals)\nâ”‚   â”‚\nâ”‚   â””â”€â”€ Trauma / Structural\nâ”‚       â”œâ”€â”€ Fight Bite (Eikenella corrodens) ğŸ¥Š\nâ”‚       â””â”€â”€ Hemarthrosis\nâ”‚\nâ”œâ”€â”€ Polyarthritis (ë‹¤ê´€ì ˆì—¼)\nâ”‚   â”œâ”€â”€ Non-Inflammatory (Mechanical)\nâ”‚   â”‚   â””â”€â”€ Osteoarthritis (OA) - Wear & Tear + Metabolic âš™ï¸\nâ”‚   â”‚\nâ”‚   â”œâ”€â”€ Inflammatory (Systemic)\nâ”‚   â”‚   â”œâ”€â”€ Rheumatoid Arthritis (RA)\nâ”‚   â”‚   â”œâ”€â”€ Spondyloarthropathies (Seronegative)\nâ”‚   â”‚   â”‚   â”œâ”€â”€ Ankylosing Spondylitis (Bamboo Spine) ğŸ‹\nâ”‚   â”‚   â”‚   â”œâ”€â”€ Reactive Arthritis (Reiter's)\nâ”‚   â”‚   â”‚   â”œâ”€â”€ Psoriatic Arthritis\nâ”‚   â”‚   â”‚   â””â”€â”€ IBD-associated\nâ”‚   â”‚   â”‚\nâ”‚   â”‚   â””â”€â”€ Vasculitis / Systemic\nâ”‚   â”‚       â”œâ”€â”€ Henoch-Schonlein Purpura (HSP) - IgA\nâ”‚   â”‚       â””â”€â”€ Cryoglobulinemia (Hep C assoc.)\nâ”‚   â”‚\nâ”‚   â””â”€â”€ Others\nâ”‚       â”œâ”€â”€ TMJ Dysfunction ğŸ¦·\nâ”‚       â””â”€â”€ Hemochromatosis (Hook-like osteophytes)\nâ”‚\nâ””â”€â”€ Synovial Fluid Analysis (The Golden Key ğŸ”‘)\n    â”œâ”€â”€ Normal: < 200 WBCs\n    â”œâ”€â”€ Non-inflammatory (OA): 200 - 2,000 WBCs\n    â”œâ”€â”€ Inflammatory (Gout/RA): 2,000 - 50,000 WBCs\n    â””â”€â”€ Septic (Infection): > 50,000 WBCs (Neutrophils > 90%) ğŸ’£`\n---\n# [Ep 01] Joint Pain Deep Dive ğŸ¤¿\n## 1.0 The Healthy Joint: An Engineering Marvel ğŸ¦´\n- **Concept:** ê±´ê°•í•œ ê´€ì ˆì€ \"ì–¼ìŒ ìœ„ì˜ ì–¼ìŒ(Ice on Ice)\"ë³´ë‹¤ ë§ˆì°°ê³„ìˆ˜ê°€ ë‚®ìŠµë‹ˆë‹¤.\n- **Structure:** Articular cartilage + Synovial fluidê°€ ì™„ë²½í•œ ìœ¤í™œìœ  ì—­í• ì„ í•˜ì—¬ ë§ˆì°°ì´ ê±°ì˜ 0ì— ê°€ê¹ìŠµë‹ˆë‹¤.\n- **Pathology:** ì´ ê¸°ê³„ì¥ì¹˜ê°€ ê³ ì¥ ë‚˜ë©´ ë”ì°í•œ ì¼ì´ ë°œìƒí•©ë‹ˆë‹¤. ë‹¨ìˆœí•œ í†µì¦(Ache)ì´ ì•„ë‹ˆë¼ ê¸°ê³„ì  ë¶•ê´´(Breakdown)ë¥¼ ì˜ë¯¸í•©ë‹ˆë‹¤.\n---\n## 2.0 Septic Arthritis (The Emergency) ğŸš¨\n**\"Never let the sun set on a Septic Joint.\"** (ì ˆëŒ€ í•´ê°€ ì§€ê²Œ ë‘ì§€ ë§ˆë¼. ì¦‰, ì¦‰ì‹œ í•´ê²°í•´ë¼!)\n### ğŸšª Doorway Thought (Vignette)\n- **Scenario:** ER ë¬¸ì„ ì—´ì—ˆì„ ë•Œ, í™˜ìê°€ ë¬´ë¦(ë˜ëŠ” ê³ ê´€ì ˆ)ì„ ë¶€ì—¬ì¡ê³  **ì ˆëŒ€ ì›€ì§ì´ë ¤ í•˜ì§€ ì•ŠìŒ(Refusal to move)**.\n- **Key Sign:** Active motion ë¿ë§Œ ì•„ë‹ˆë¼ **Passive motion** (ì˜ì‚¬ê°€ ë‹¤ë¦¬ë¥¼ ë“¤ì–´ ì˜¬ë¦¬ë ¤ í•  ë•Œ)ì—ë„ ìì§€ëŸ¬ì§€ëŠ” ë¹„ëª…ì„ ì§€ë¦„.\n- **Visual:** Red, Hot, Swollen Joint (Monoarticular).\n### ğŸ©º Diagnosis & Workup\n- **Gold Standard:** **Arthrocentesis (Joint Aspiration)**. ë°”ëŠ˜ ê½‚ì•„ì„œ ë¬¼ ë½‘ì•„ì•¼ í•©ë‹ˆë‹¤! â˜…\n    - **The Magic Number:** **WBC > 50,000/mm3** (Neutrophils > 90%)\n    - *Caveat:* ë¥˜ë§ˆí‹°ìŠ¤ ê´€ì ˆì—¼(RA)ì´ë‚˜ í†µí’(Gout) ë°œì‘ ì‹œì—ë„ 50k ê·¼ì²˜ê¹Œì§€ ê°ˆ ìˆ˜ ìˆì§€ë§Œ, 50kê°€ ë„˜ìœ¼ë©´ ì¼ë‹¨ **Septic**ìœ¼ë¡œ ê°„ì£¼í•˜ê³  ì¹˜ë£Œí•´ì•¼ í•¨.\n- **Mechanism:** ë°±í˜ˆêµ¬(Neutrophil)ê°€ ë°•í…Œë¦¬ì•„ë¥¼ ì£½ì´ë ¤ê³  íš¨ì†Œ(Proteolytic enzymes)ë¥¼ ë¿œì–´ë‚´ëŠ”ë°, ì´ê²Œ ë°•í…Œë¦¬ì•„ë§Œ ì£½ì´ëŠ” ê²Œ ì•„ë‹ˆë¼ **ì—°ê³¨(Cartilage)ë„ ë…¹ì—¬ë²„ë¦¼**.\n    - **Time limit:** 24~48ì‹œê°„ ì•ˆì— ê´€ì ˆì´ ì˜êµ¬ì ìœ¼ë¡œ íŒŒê´´ë  ìˆ˜ ìˆìŒ.\n### ğŸ’Š Management (Next Best Step)\n1. **Tap the Joint (Aspiration):** ì§„ë‹¨ ë° ì••ë ¥ í•´ì†Œ(Pain relief).\n2. **Antibiotics:** ì¦‰ì‹œ ì‹œì‘ (Empiric).\n    - Adult: **Vancomycin + Ceftriaxone** (Staph aureus & Gram negatives ì»¤ë²„).\n3. **Surgical Drainage (Washout):** ê³ ë¦„(Pus)ì„ ì”»ì–´ë‚´ì•¼ í•¨. \"Drain the abscess.\"\n### ğŸ‘¶ Pediatric Considerations (The Limping Child)\n- **Vignette:** 2ì„¸ ì•„ì´ê°€ ë‹¤ë¦¬ë¥¼ ì ˆê±°ë‚˜(Limping), ì•„ì˜ˆ ê¸°ì–´ ë‹¤ë‹ˆì§€ ì•Šìœ¼ë ¤ í•¨(Refuses to crawl).\n- **Differential:** Septic Arthritis vs **Transient Synovitis** (ì¼ê³¼ì„± í™œë§‰ì—¼ - \"Hipì˜ ê°ê¸°\").\n    - Transient Synovitis: ë°”ì´ëŸ¬ìŠ¤ ê°ì—¼ í›„ ë°œìƒ, ì €ì ˆë¡œ ì¢‹ì•„ì§ (Benign).\n- **Kocher Criteria (Septic Hip ê°ë³„ë²•) â˜…:**\n    1. **Non-weight bearing:** ì•„ì˜ˆ ê±·ì§€ ëª»í•¨.\n    2. **Fever:** > 38.5Â°C (101.3Â°F).\n    3. **ESR:** > 40 mm/hr.\n    4. **WBC:** > 12,000 (Serum).\n    - *Probability:* 4ê°œ ë‹¤ ìˆìœ¼ë©´ 99% Septic Arthritis â†’ **OR(ìˆ˜ìˆ ì‹¤)ë¡œ ì§í–‰**.\n- Diagnosis is unclear â†’ **bilateral hip sonography**\n    - Even if ì¦ìƒì´ í•œìª½ì— ìˆì–´ë„ ì–‘ìª½ì— fluid in the both hips in Transient synovitis\n    - ì¦ìƒì´ í•œìª½ì—ë§Œ ìˆìœ¼ë©´ â†’ septic arthritis í™•ë¥  ì˜¬ë¼ê° â†’ diagnostic arthocentesis","subject":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","page_title":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","episode":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","section_path":["LM_OSRHM 30046f2986ee8098921dc4e04b63ee22"],"source_doc_id":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","source_page":null,"source_anchor":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22-41","focus_area":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","tags":["usmle-step2","core","diagnosis","treatment","pathophysiology"]}
{"chunk_type":"transcript_chunk","text":"---\n## 3.0 Fight Bite (Clenched Fist Injury) ğŸ¥Š\n**\"The Lie in the History.\"** í™˜ìëŠ” ê±°ì§“ë§ì„ í•©ë‹ˆë‹¤.\n### ğŸšª Doorway Thought\n- **Scenario:** ë‚¨ìê°€ ì†ë“±(Knuckle, MCP joint)ì— ì‘ì€ ìƒì²˜(Laceration)ë¥¼ ì…ê³  ì˜´. \"ì„¤ê±°ì§€í•˜ë‹¤ ë² ì˜€ì–´ìš”\" í˜¹ì€ \"ë„˜ì–´ì¡Œì–´ìš”\"ë¼ê³  í•¨.\n- **Truth:** ëˆ„êµ°ê°€ì˜ **ì´ë¹¨(Tooth)**ì„ ì£¼ë¨¹ìœ¼ë¡œ ë•Œë¦° ê²ƒì„. (Human Bite).\n### ğŸ¦  Pathophysiology\n- **Anatomy:** ì£¼ë¨¹ì„ ì¥ì—ˆì„ ë•Œ(Fist), í˜ì¤„(Extensor tendon)ê³¼ í”¼ë¶€ê°€ íŒ½íŒ½í•˜ê²Œ ë‹¹ê²¨ì§ â†’ ì´ë¹¨ì´ ëš«ê³  ë“¤ì–´ê° â†’ ê´€ì ˆë‚­(Joint capsule)ì— ê·  ì£¼ì….\n- **The Trap:** ì†ì„ í´ë©´(Relax), í˜ì¤„ê³¼ í”¼ë¶€ê°€ ë¯¸ë„ëŸ¬ì ¸ ì œìë¦¬ë¡œ ëŒì•„ì˜¤ë©´ì„œ **êµ¬ë©ì´ ì–´ê¸‹ë‚¨ (Sliding Door effect)**.\n    - ê²°ê³¼: ê· ì´ ê¹Šìˆ™í•œ ê³³(í˜ê¸°ì„± í™˜ê²½)ì— ê°‡í˜€ë²„ë¦¼. ğŸ¦ ğŸ”’\n- **Bug:** **Eikenella corrodens** (Human mouth flora, Anaerobe) + Staph/Strep. \"Poly-microbial party.\"\n### ğŸš« Management Rules\n- **Absolute Rule:** **NEVER SUTURE (ì ˆëŒ€ ë´‰í•© ê¸ˆì§€).** ğŸ§µâŒ\n    - ë´‰í•©í•˜ë©´ ë†ì–‘(Abscess)ì„ ë°€ë´‰í•´ë²„ë¦¬ëŠ” ê¼´.\n- **Treatment:**\n    1. **Irrigation & Debridement:** ì”»ì–´ë‚´ê³  ì£½ì€ ì¡°ì§ ì œê±°.\n    2. **Antibiotics:** **Amoxicillin-Clavulanate (Augmentin)** (PO) or **Ampicillin-Sulbactam (Unasyn)** (IV).\n    3. **Secondary Intention:** ìƒì²˜ê°€ ì—´ë¦° ì±„ë¡œ ì•„ë¬¼ê²Œ ë‘ .\n---\n## 4.0 Disseminated Gonococcal Infection (DGI) ğŸ†ğŸ”¥\n- *\"Sexually Active Young Adult\"**ì˜ ë‹¨ê´€ì ˆì—¼ ì›ì¸ 1ìˆœìœ„.\n### ğŸšª Doorway Thought\n- **Presentation 1:** Purulent Monoarthritis (Septic Kneeì²˜ëŸ¼ ë³´ì„).\n- **Presentation 2 (The Triad):**\n    1. **Tenosynovitis:** ì†ëª©, ë°œëª© í˜ì¤„ì˜ ì—¼ì¦/í†µì¦.\n    2. **Dermatitis:** Pustules (ê³ ë¦„ì§‘) on extremities (íŒ”ë‹¤ë¦¬ì— ë“œë¬¸ë“œë¬¸ ë‚œ ì—¬ë“œë¦„ ê°™ì€ ê²ƒ).\n    3. **Migratory Polyarthralgia:** ì—¬ê¸°ì €ê¸° ê´€ì ˆì´ ëŒì•„ê°€ë©° ì•„í””.\n### ğŸ•µï¸ Diagnosis Dilemma\n- **Trap:** ë¬´ë¦ì—ì„œ ë¬¼ì„ ë½‘ì•„ë„ ë°°ì–‘(Culture)ì´ **ìŒì„±(Negative)**ì¸ ê²½ìš°ê°€ ë§ìŒ. (ê· ì´ ê¹Œë‹¤ë¡œì›€ - Fastidious).\n- **Gold Standard:** **NAAT (Nucleic Acid Amplification Test)**.\n    - **Tip:** ë¬´ë¦ë§Œ ì°Œë¥´ì§€ ë§ê³ , **Urethra (ìš”ë„), Rectum (í•­ë¬¸), Pharynx (ëª©êµ¬ë©)** ë“± ê· ì´ ë“¤ì–´ì™”ì„ ë²•í•œ ëª¨ë“  ì…êµ¬ë¥¼ ë‹¤ ê¸ì–´ì•¼ í•¨(Swab).\n### ğŸ’Š Treatment\n- **IV Ceftriaxone** (Gonorrhea) + **Azithromycin or Doxycycline** (Chlamydia Co-infection ì»¤ë²„).\n---\n## 5.0 Osteoarthritis (OA) ğŸ‘µâš™ï¸","subject":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","page_title":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","episode":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","section_path":["LM_OSRHM 30046f2986ee8098921dc4e04b63ee22"],"source_doc_id":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","source_page":null,"source_anchor":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22-61","focus_area":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","tags":["usmle-step2","core","diagnosis","treatment","pathophysiology"]}
{"chunk_type":"transcript_chunk","text":"**\"Wear and Tear... and Repair?\"**\n### ğŸšª Doorway Thought\n- **Patient:** 40ëŒ€ ì´ìƒ (ë‚˜ì´ ë“¦).\n- **Symptom:** **Pain worse with use**, better with rest. (ì“°ë©´ ì•„í”„ê³  ì‰¬ë©´ ë‚«ë‹¤).\n- **Morning Stiffness:** **< 30 minutes** (ì§§ë‹¤. ì»¤í”¼ í•œ ì” ë§ˆì‹¤ ì‹œê°„ì´ë©´ í’€ë¦¼). â˜•ï¸\n### ğŸ§¬ Concept Update\n- ë‹¨ìˆœí•œ \"íƒ€ì´ì–´ ë§ˆëª¨\"ê°€ ì•„ë‹˜. ì—°ê³¨ ì„¸í¬(Chondrocyte)ê°€ ì†ìƒì„ ë³µêµ¬í•˜ë ¤ê³  íš¨ì†Œë„ ë‚´ê³  ì—¼ì¦ ë¬¼ì§ˆë„ ë‚´ëŠ” **Active Metabolic Process (ì‹¤íŒ¨í•œ ë³µêµ¬ ê³¼ì •)**ì„.\n- **Synovial Fluid:** **Non-inflammatory** (WBC 200 ~ 2,000). ë§‘ê±°ë‚˜ ì˜…ì€ í˜¸ë°•ìƒ‰.\n### âœ‹ Physical Exam (Hands)\n- **DIP Joint:** **Heberden's Nodes** (ì†ê°€ë½ ëë§ˆë”” íˆ­ íŠ€ì–´ë‚˜ì˜´).\n- **PIP Joint:** **Bouchard's Nodes** (ì¤‘ê°„ ë§ˆë””).\n- **CMC Joint:** ì—„ì§€ì†ê°€ë½ ë¿Œë¦¬ (Squaring of the thumb).\n- **Crucial Distinction:** **Spares the MCPs** (Knuckleì€ ì¹¨ë²” ì•ˆ í•¨. ì—¬ê¸°ê°€ ì•„í”„ë©´ RA ì˜ì‹¬!).\n### ğŸ’ Iron Overload Hint (Hemochromatosis)\n- ë§Œì•½ \"OA ê°™ì€ë°\" **2nd & 3rd MCP joint**ì— **Hook-like Osteophytes (ê°ˆê³ ë¦¬ ê°™ì€ ë¼ˆ ëŒê¸°)**ê°€ ë³´ì¸ë‹¤?\n- **Diagnosis:** **Hereditary Hemochromatosis** (ìœ ì „ì„± í˜ˆìƒ‰ì†Œì¹¨ì°©ì¦) ê°•ë ¥ ì˜ì‹¬! ğŸ§²\n### ğŸªœ Management (Step-up Approach)\n1. **Step 1 (Non-Pharm):** **Weight Loss & Exercise.** (ê°€ì¥ ì¤‘ìš”! â˜…)\n    - ì²´ì¤‘ 1kg ì¤„ì´ë©´ ë¬´ë¦ ì••ë ¥ 4kg ê°ì†Œ.\n    - Quadriceps strengthening (ëŒ€í‡´ì‚¬ë‘ê·¼ ê°•í™”) â†’ ê´€ì ˆ ì•ˆì •í™”.\n2. **Step 2 (Topical):** **Topical NSAIDs** (Diclofenac gel) - ì „ì‹  ë¶€ì‘ìš© ì ìŒ.\n3. **Step 3 (Oral):** **Oral NSAIDs** (Naproxen etc.) or **Duloxetine** (SNRI, ë§Œì„± í†µì¦ ì¡°ì ˆ).\n    - *Note:* Acetaminophen(Tylenol)ì€ ì´ì œ 1ì°¨ ì„ íƒì œê°€ ì•„ë‹˜ (íš¨ê³¼ ë¯¸ë¯¸).\n4. **Step 4 (End Stage):** **Total Joint Arthroplasty (ì¸ê³µê´€ì ˆ ì¹˜í™˜ìˆ )**. ì‚¶ì˜ ì§ˆì´ ë°”ë‹¥ì¼ ë•Œ.\n---\n## 6.0 Spondyloarthropathies (Seronegative) ğŸ§˜â€â™‚ï¸\n**\"The Inflammatory Back Pain.\"**\n### 6.1 Ankylosing Spondylitis (ê°•ì§ì„± ì²™ì¶”ì—¼) ğŸ‹\n- **Vignette:** ì Šì€ ë‚¨ì„± (<40ì„¸). ë§Œì„± í—ˆë¦¬ í†µì¦.\n- **Pain Pattern:** **Worse with Rest, Better with Exercise.** (OAì™€ ì •ë°˜ëŒ€!). ë°¤ì— ì•„íŒŒì„œ ê¹¸.\n- **Pathology:** **Enthesitis** (ì¸ëŒ€/í˜ì¤„ì´ ë¼ˆì— ë¶™ëŠ” ìë¦¬ì˜ ì—¼ì¦).\n- **Imaging:** sacroiliitis (ì²œì¥ê´€ì ˆì—¼) â†’ **Bamboo Spine** (ì²™ì¶”ê°€ ëŒ€ë‚˜ë¬´ì²˜ëŸ¼ êµ³ìŒ).\n- **Association:** **HLA-B27**. **Anterior Uveitis** (ëˆˆ ì¶©í˜ˆ, í†µì¦ - ì¦‰ì‹œ ì•ˆê³¼!).\n- **Treatment:** NSAIDs (1st line) â†’ ì‹¤íŒ¨í•˜ë©´ **TNF Inhibitors** (Infliximab, Etanercept). â†’ anti IL-17 (secukinumab)\n### 6.2 Reactive Arthritis (Reiter's Syndrome) ğŸ¦ \n- **Mnemonic:** **\"Can't see, can't pee, can't climb a tree.\"**\n    - Conjunctivitis/Uveitis (Can't see)\n    - Urethritis (Can't pee)\n    - Arthritis (Can't climb a tree)\n- **Trigger:** GI infection (Campylobacter, Salmonella, Shigella, Yersinia) or Chlamydia.\n---\n## 7.0 Vasculitis & Systemic Causes ğŸ©¸","subject":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","page_title":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","episode":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","section_path":["LM_OSRHM 30046f2986ee8098921dc4e04b63ee22"],"source_doc_id":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","source_page":null,"source_anchor":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22-81","focus_area":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","tags":["usmle-step2","core","diagnosis","treatment","mnemonic","tree"]}
{"chunk_type":"transcript_chunk","text":"### 7.1 Henoch-Schonlein Purpura (HSP) / IgA Vasculitis\n- **Patient:** ì£¼ë¡œ ì†Œì•„ (Pediatric).\n- **Tetrad:**\n    1. **Palpable Purpura:** ì—‰ë©ì´(Buttocks)ì™€ ë‹¤ë¦¬ ë’¤ìª½ì— ë§Œì ¸ì§€ëŠ” ìë°˜.\n    2. **Arthritis/Arthralgia:** ê´€ì ˆí†µ.\n    3. **Abdominal Pain:** ë°° ì•„í”” (Intussusception ìœ„í—˜). (Ileo-Ileal)\n    4. **Renal Disease:** **IgA Nephropathy** (í˜ˆë‡¨).\n### 7.2 Cryoglobulinemia â„ï¸\n- **Link:** **Hepatitis C (HCV)**ì™€ ê°•ë ¥í•œ ì—°ê´€ì„±.\n- **Mechanism:** ì°¨ê°€ìš´ ì˜¨ë„ì—ì„œ ë‹¨ë°±ì§ˆ(Cryoglobulins)ì´ ë­‰ì³ì„œ í˜ˆê´€ ë§‰ìŒ.\n- **Labs:** **Low C4**, Positive Rheumatoid Factor (RF), HCV RNA (+).\n    - cf. RFì–‘ì„±ì´ì—¬ë„ RAë©´ C4ì •ìƒì„. RFì–‘ì„±ì¸ë° C4ì •ìƒì´ë©´? â†’ HCV ê¸°ì™•ë ¥ í™•ì¸í•˜ê³  crygolobulinemiaì˜ì‹¬!\n- **Sx:** Palpable Purpura, Weakness, Arthralgias (Melted's Triad).\n---\n## 8.0 TMJ Dysfunction (Temporomandibular Joint) ğŸ¦·\n- **Symptom:** í„±ì—ì„œ \"ë”±ë”±\" ì†Œë¦¬(Clicking/Popping), ì”¹ì„ ë•Œ í†µì¦, ê·€ í†µì¦(Otalgia).\n- **Cause:** **Bruxism** (ì´ê°ˆì´), ìŠ¤íŠ¸ë ˆìŠ¤.\n- **Exam:** ì… ë²Œë¦´ ë•Œ í„± ê·¼ìœ¡ ì••í†µ, ì†Œë¦¬ í™•ì¸.\n- **Tx:** Conservative first! Soft diet (ë¶€ë“œëŸ¬ìš´ ìŒì‹), Night guard (ë§ˆìš°ìŠ¤í”¼ìŠ¤), NSAIDs.\n---\n## âš¡ï¸ RAPID FIRE RECAP (Summary Table)\n| **Condition** | **Key Vignette / Symptom** | **Synovial Fluid WBC** | **Gold Standard / Next Step** | **Treatment Highlights** |\n| --- | --- | --- | --- | --- |\n| **Septic Arthritis** | Red, Hot, Single Joint, **Refusal to move** | **> 50,000** (>90% PMN) | **Arthrocentesis** (Tap it!) | **IV Abx + Washout (Drainage)** |\n| **Gout** | Podagra (Big toe), sudden onset | 2,000 - 50,000 (Crystals) | Polarized Microscopy (Needle shape, Neg birefringent) | NSAIDs, Colchicine, Steroids (Acute) |\n| **OA** | Older, Worse with use, DIP/PIP involved | < 2,000 (Non-inflam) | X-ray (Joint space narrowing, Osteophytes) | **Weight Loss**, Exercise, NSAIDs |\n| **Fight Bite** | Cut on knuckle (MCP), punched mouth | N/A | History taking (Look for lie) | **Augmentin**, **NEVER SUTURE** |\n| **DGI** | Sexually active, Triad (Tenosynovitis, Rash, Polyarthralgia) | Often Negative culture | **NAAT** (Urethra, Rectum, Throat) | Ceftriaxone + Azithro/Doxy |\n| **Ankylosing Spondylitis** | Young male, Back pain better w/ exercise | N/A | X-ray (Sacroiliitis), HLA-B27 | NSAIDs â†’ TNF Inhibitors |\n| **HSP (IgA)** | Kid, Palpable purpura on butt, Abd pain | N/A | Clinical Dx, Urinalysis (Hematuria) | Supportive (Hydration, NSAIDs) |\n### ğŸ’¡ Final Wisdom\n**(Confidence: 1.0) - All content extracted from audio and structured for USMLE prep.**\n# ğŸ©º **USMLE Step 2 CK: Systemic Autoimmune Disorders Deep Dive**\n**(Rheumatoid Arthritis, SLE, Felty, MCTD)**\n---\n---","subject":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","page_title":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","episode":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","section_path":["LM_OSRHM 30046f2986ee8098921dc4e04b63ee22"],"source_doc_id":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","source_page":null,"source_anchor":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22-101","focus_area":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","tags":["usmle-step2","core","diagnosis","treatment","pathophysiology"]}
{"chunk_type":"transcript_chunk","text":"### ğŸŒ³ **Big Picture: Classification & Mental Model**\nUSMLEì—ì„œ ë¥˜ë§ˆí‹°ìŠ¤í•™ì„ ì ‘ê·¼í•  ë•Œ ê°€ì¥ ì¤‘ìš”í•œ ê²ƒì€ **\"Pattern Recognition\"**ê³¼ **\"Antibody Correlation\"**ì…ë‹ˆë‹¤. ë‹¨ìˆœíˆ ê´€ì ˆì´ ì•„í”„ë‹¤ê°€ ì•„ë‹ˆë¼, ì–´ë–¤ íŒ¨í„´ìœ¼ë¡œ ì•„í”ˆì§€, ê·¸ë¦¬ê³  ì–´ë–¤ ì¥ê¸°ê°€ ê°™ì´ ë§ê°€ì§€ëŠ”ì§€ë¥¼ ë´ì•¼ í•©ë‹ˆë‹¤.\nPlaintext\n`SYSTEMIC AUTOIMMUNE DISORDERS (The \"Body attacking itself\")\nâ”‚\nâ”œâ”€â”€ JOINT-PREDOMINANT (Erosive)\nâ”‚   â””â”€â”€ Rheumatoid Arthritis (RA)\nâ”‚       â”œâ”€â”€ Key Path: Synovial Pannus (Inflammation)\nâ”‚       â”œâ”€â”€ Key Symptom: Morning Stiffness > 1hr (\"Gel Phenomenon\")\nâ”‚       â””â”€â”€ Complications:\nâ”‚           â”œâ”€â”€ Felty Syndrome (RA + Neutropenia + Splenomegaly)\nâ”‚           â””â”€â”€ C1-C2 Instability (Life Threatening!)\nâ”‚\nâ”œâ”€â”€ MULTI-SYSTEM (Vascultis/Organ Damage)\nâ”‚   â””â”€â”€ Systemic Lupus Erythematosus (SLE)\nâ”‚       â”œâ”€â”€ Key Path: Immune Complex Deposition (Type III)\nâ”‚       â”œâ”€â”€ Key Vibe: \"Fatigued Young Woman with Multiorgan Issues\"\nâ”‚       â”œâ”€â”€ Specifics: Malar Rash, Nephritis, Cerebritis\nâ”‚       â””â”€â”€ Variant: Drug-Induced Lupus (Histone Ab)\nâ”‚\nâ”œâ”€â”€ OVERLAP SYNDROMES\nâ”‚   â””â”€â”€ Mixed Connective Tissue Disease (MCTD)\nâ”‚       â”œâ”€â”€ Key Path: Features of SLE + Systemic Sclerosis + Polymyositis\nâ”‚       â””â”€â”€ Marker: Anti-U1-RNP\nâ”‚\nâ””â”€â”€ THROMBOTIC/OBSTETRIC\n    â””â”€â”€ Antiphospholipid Syndrome (APLA)\n        â”œâ”€â”€ Key Path: Hypercoagulable State\n        â””â”€â”€ Outcome: Clots (Arterial/Venous) + Pregnancy Loss`\n---\n![image.png](LM_OSRHM/image.png)\n- 50k ë„˜ìœ¼ë©´ septic joint arthritis until proven otherwise\n# 1. Rheumatoid Arthritis (RA) ğŸ¦´ğŸ”¥\n*The \"Morning Paralysis\" Disease*\n### ğŸšª **Doorway Thought (Vignette Anchor)**\n40-50ëŒ€ ì—¬ì„±ì´ ì•„ì¹¨ì— ì¼ì–´ë‚¬ëŠ”ë° ì¹¨ëŒ€ ëì— ê±¸í„°ì•‰ì•„ ìˆìŠµë‹ˆë‹¤. ë‹¨ìˆœíˆ í”¼ê³¤í•œ ê²Œ ì•„ë‹ˆë¼ **\"Gel Phenomenon\"** ë•Œë¬¸ì— ì›€ì§ì¼ ìˆ˜ê°€ ì—†ìŠµë‹ˆë‹¤. ì†ì´ ì‹œë©˜íŠ¸ì— êµ³ì€ ê²ƒì²˜ëŸ¼ ë»£ë»£í•˜ë©°, ì´ ì¦ìƒì´ **1ì‹œê°„ ì´ìƒ(>1hr)** ì§€ì†ë©ë‹ˆë‹¤.\n### ğŸ” **Clinical Features & \"The Vibe\"**\n- **Stiffness Duration:** â˜… **> 1 Hour** (ê°€ì¥ ì¤‘ìš”í•œ êµ¬ë³„ì ). OAëŠ” ë³´í†µ 15-30ë¶„ ì´ë‚´ì— í’€ë¦¼.\n- **Joint Pattern:**\n    - **Symmetric** (ëŒ€ì¹­ì ).\n    - **Small Joints:** MCP, PIP, Wrist ì¹¨ë²”.\n    - **SPARES DIP:** â˜… DIP(ì†ê°€ë½ ëë§ˆë””)ëŠ” ì¹¨ë²”í•˜ì§€ ì•ŠìŒ! (DIP ì¹¨ë²”ì€ OAì˜ Heberden's node).\n- **Texture:** ë§Œì ¸ë³´ë©´ **Soft, Warm, Boggy** (Sponge ê°™ìŒ). ë°˜ë©´ OAëŠ” Hard, Bonyí•¨.\n### ğŸ§ª **Diagnosis (Workup)**\n| **Lab Test** | **Sensitivity/Specificity** | **Notes** |\n| --- | --- | --- |\n| **RF (Rheumatoid Factor)** | Sensitive | ë¯¼ê°ë„ëŠ” ë†’ì§€ë§Œ íŠ¹ì´ë„ê°€ ë‚®ìŒ (ë‹¤ë¥¸ ë³‘ì—ì„œë„ ì–‘ì„± ê°€ëŠ¥). |\n| **Anti-CCP** | **Specific (Gold Standard)** | â˜… **ê°€ì¥ ì¤‘ìš”í•œ í™•ì§„ ê²€ì‚¬.** RAì— ë§¤ìš° íŠ¹ì´ì ì„. |\n| **ESR / CRP** | Inflammation Markers | ì§ˆë³‘ì˜ í™œì„±ë„(Activity)ë¥¼ ëª¨ë‹ˆí„°ë§í•˜ëŠ” ë° ìœ ìš©. |\n### âš ï¸ **Key Complications (High Yield)**\n1. **Lungs:** Pulmonary Nodules, Pleural Effusion, **Fibrosis (Interstitial Lung Disease)**.\n2. **Eyes:** **Scleritis** (Deep, boring eye PAINFUL - ì‘ê¸‰!), Episcleritis.\n3. **Heart:** Accelerated Atherosclerosis (ì‹¬í˜ˆê´€ ì§ˆí™˜ ìœ„í—˜ ê¸‰ì¦ -> MI, Stroke ì£¼ì˜).\n4. **Cervical Spine (C1-C2 Instability):** â˜… **USMLE KILLER QUESTION**\n    - C1-C2ë„ synovial joint.\n    - spinal compression â†’ UMN lesions â†’ weakness and spastic paralysis in all 4 limbs.\n        - ê°ê°ì´ ì•½í•´ì§€ê³ , ëª¸ì´ ì•½í•´ì§€ë©´ì„œ êµ³ì–´ìš”\n    - Hoffman sign to test UMN lesion: ê°€ìš´ë° ì†ê°€ë½ ì†í†±ì„ ì•„ë˜ë¡œ ë”¸ê¹í•˜ë©´, ì—„ì§€ì™€ ë‘ë²ˆì§¸ ì†ê°€ë½ì´ adduction, flexion.\n    - **Scenario:** RA í™˜ìê°€ ìˆ˜ìˆ (ì˜ˆ: ë‹´ë‚­ì ˆì œìˆ )ì„ ë°›ìœ¼ëŸ¬ ì˜´. ë§ˆì·¨ê³¼ ì˜ì‚¬ê°€ ì‚½ê´€(Intubation)ì„ ìœ„í•´ ê³ ê°œë¥¼ ë’¤ë¡œ ì –íˆë©´?\n    - **Risk:** Dens(Odontoid process)ê°€ ì²™ìˆ˜(Spinal cord)ë¥¼ ëˆŒëŸ¬ **ì‚¬ì§€ë§ˆë¹„(Quadriplegia)** í˜¹ì€ ì‚¬ë§ ìœ ë°œ.\n    - **Next Best Step:** ìˆ˜ìˆ  ì „ **Cervical Spine Flexion/Extension X-ray** í•„ìˆ˜!\n### ğŸ’Š **Treatment Strategy**\n- **Symptom Control:** NSAIDs, Steroids (Bridge therapy).\n- **DMARDs (Disease Modifying Anti-Rheumatic Drugs):**\n    - **Methotrexate (MTX):** â˜… **King of RA Treatment.** (First-line).\n        - *Mechanism:* Dihydrofolate reductase inhibitor (Folate antagonist).\n        - *Toxicities:* Hepatotoxicity, Stomatitis (ì…ì•ˆ í—ìŒ), **Bone Marrow Suppression**\n            - Pulmonary Fibrosis (Methotrexate induced lung injury)\n                - note: RAì— ì˜í•œ Pulmonary fibrosisë‘ êµ¬ë¶„í•´ì•¼ë¨. (RA: chronic slow scarring)\n                - Acute hypersensitivity reaction, therefore not dose dependent.\n                - Pneumoniaeì²˜ëŸ¼ ë³´ì„. fever, SOB.\n                - BAL: lymphocytosisê°€ ë³´ì„. Peripheral blood: eosinophilia\n        - *Prevention:* ë°˜ë“œì‹œ **Folate (Folic acid)**ë¥¼ ê°™ì´ ì²˜ë°©í•´ì•¼ í•¨!\n        - CIx: Renal, Hepatic disease, Pregnancy\n            - HBV, HCV í™˜ìì—ì„œ ê¸ˆê¸°. ë¯¸ë¦¬ ê²€ì‚¬í•´ì•¼ë¨.\n    - **Biologics:** Anti-TNF agents (Etanercept, Infliximab, Adalimumab).\n        - *Must Do:* ì‹œì‘ ì „ **TB Screening (Latent TB)**, Hep B/C Screening í•„ìˆ˜! (ì¬í™œì„±í™” ìœ„í—˜).\n    - Hydroxychloroquine: lupusë¿ì•„ë‹ˆë¼ RAì—ì„œë„ ë³´ì¡°ì¹˜ë£Œì •ë„ë¡œ ì•½í•œ í™˜ìì—ì„œ ì“°ì¼ ìˆ˜ ìˆìŒ.\n        - EYE damage ğŸ‘€Â ëˆˆì— ìŒ“ì„. Therefore, opthalmologic evaluation\n---","subject":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","page_title":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","episode":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","section_path":["LM_OSRHM 30046f2986ee8098921dc4e04b63ee22"],"source_doc_id":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","source_page":null,"source_anchor":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22-121","focus_area":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","tags":["usmle-step2","core","diagnosis","treatment","pathophysiology","mnemonic"]}
{"chunk_type":"transcript_chunk","text":"# 2. Felty Syndrome ğŸ“‰ğŸ¦ \n*The \"Burned-Out\" RA Patient*\n### ğŸšª **Clinical Vignette**\nìˆ˜ì‹­ ë…„ê°„ RAë¥¼ ì•“ì•„ì˜¨ í™˜ì. ê´€ì ˆì€ ì´ë¯¸ ë‹¤ ë§ê°€ì ¸ì„œ ë’¤í‹€ë ¤ ìˆìŒ(**Erosive Arthritis**).\n*ê·¸ëŸ°ë° ì´ë²ˆì—” ê´€ì ˆí†µì´ ì•„ë‹ˆë¼ **ë°˜ë³µë˜ëŠ” ê°ì—¼(Pneumonia, Skin infection)**ìœ¼ë¡œ ë‚´ì›í•¨.*\n### âš¡ **The Triad (Must Memorize)**\n1. **Rheumatoid Arthritis** (Long-standing, severe).\n2. **Splenomegaly** (ë¹„ì¥ë¹„ëŒ€).\n3. **Neutropenia** (ANC < 2,000 - í˜¸ì¤‘êµ¬ ê°ì†Œ).\n# 3. Systemic Lupus Erythematosus (SLE) ğŸ¦‹ğŸº\n*The \"Great Imitator\" with a Migratory Pain*\n### ğŸšª **Doorway Thought (Vignette Anchor)**\n20-30ëŒ€ ì Šì€ ì—¬ì„±. ë‹¨ìˆœíˆ ê´€ì ˆë§Œ ì•„í”ˆ ê²Œ ì•„ë‹ˆë¼ **ê·¹ì‹¬í•œ í”¼ë¡œê°(Deep Fatigue)**ì„ í˜¸ì†Œí•¨. ì–¼êµ´ì—ëŠ” ë‚˜ë¹„ ëª¨ì–‘ ë°œì§„(**Malar Rash**)ì´ ìˆê³ , í–‡ë¹›ì„ ë°›ìœ¼ë©´ í”¼ë¶€ê°€ ë’¤ì§‘ì–´ì§(**Photosensitivity**).\n### ğŸ©º **Key Symptoms & Systemic Fire**\n- **Skin:** Malar Rash (â˜… **Spares Nasolabial Folds** - íŒ”ìì£¼ë¦„ì€ ì¹¨ë²” ì•ˆ í•¨!). Discoid Rash (Scarring ìœ ë°œ).\n- **Joints:** **Migratory â˜… Arthritis** (ëŒì•„ë‹¤ë‹ˆëŠ” í†µì¦)(RAë‘ ì°¨ì´)\nRAì™€ ë‹¬ë¦¬ **Non-erosive** (ë¼ˆë¥¼ ê°‰ì•„ë¨¹ì§€ ì•ŠìŒ). *Jaccoud Arthropathy* (ì†ê°€ë½ì´ íœ˜ì§€ë§Œ í´ë©´ í´ì§).\n- **Serositis:** Pleuritis (ìˆ¨ ì‰´ ë•Œ ì•„í””), Pericarditis.\n- **Heart:** Libman-Sacks Endocarditis (LSE) - \"Vegetations on **BOTH** sides of the valve\".\n- Pregnancy: 3rd trimester, protienuria, hypertension\n    - r/o Preeclampsia?â€¦?\n    - êµ¬ë¶„í•´ì•¼ ì¹˜ë£Œë¥¼ ê³ ë¦„. Steroid (SLE) vs delivery (preeclampsia)\n    - SLEì—ì„œëŠ” ICë¥¼ í˜•ì„±í•˜ê³  C3, C4 low. Preeclampsiaì—ì„œëŠ” ë³´ì²´ ì •ìƒ\n| in ğŸ¤° | SLE | Preeclampsia |\n| --- | --- | --- |\n| ë³´ì²´ | ê°ì†Œ\n(IC í˜•ì„±ìœ¼ë¡œ ì¸í•œ ë³´ì²´ ì†Œëª¨) | ì •ìƒ |\n| Urinalysis | Active inflammation\nâ†’ RBC cast | Cast ì—†ìŒ |\n| Tx. | Steroid | Delivery |\n### ğŸš¨ **Lupus Nephritis (The Silent Killer)**\n- ê°€ì¥ ì¤‘ìš”í•œ ì˜ˆí›„ ì¸ì. ì†Œë³€ì—ì„œ **Proteinuria**, Hematuria, **Casts** ë°œê²¬.\n- **Next Best Step:** â˜… **Renal Biopsy** (ì‹ ì¥ ì¡°ì§ê²€ì‚¬).\n    - *Why?* Lupus NephritisëŠ” Class I ~ VIê¹Œì§€ ë‹¨ê³„ê°€ ìˆê³ , ë‹¨ê³„ì— ë”°ë¼ ì¹˜ë£Œ(Steroid only vs. Cyclophosphamide/Mycophenolate)ê°€ ì™„ì „íˆ ë‹¬ë¼ì§. ë‹¨ìˆœíˆ ì†Œë³€ê²€ì‚¬ë§Œìœ¼ë¡œëŠ” ì¹˜ë£Œ ê²°ì •ì„ ë‚´ë¦´ ìˆ˜ ì—†ìŒ.\n### ğŸ§ª **Diagnosis (Antibodies)**\n| **Antibody** | **Characteristics** |\n| --- | --- |\n| **ANA (Anti-Nuclear Ab)** | **Sensitive (>95%)**. Screening Test. ìŒì„±ì´ë©´ SLE ì•„ë‹ í™•ë¥  ë†’ìŒ. |\n| **Anti-dsDNA** | **Specific**. â˜… **Disease Activityì™€ ë¹„ë¡€í•¨** (ìˆ˜ì¹˜ ë†’ìœ¼ë©´ ì‹ ì¥ì—¼ í™œì„±ë„ ë†’ìŒ). |\n| **Anti-Smith** | **Specific**. ì§ˆë³‘ í™œì„±ë„ì™€ëŠ” ë¬´ê´€í•˜ì§€ë§Œ ì§„ë‹¨ì  ê°€ì¹˜ ë†’ìŒ. |\n| **C3, C4 Levels** | **Low** in active flare. (ë³´ì²´ê°€ ë©´ì—­ë³µí•©ì²´ í˜•ì„±ì— ì†Œëª¨ë¨). |\n### ğŸ’Š **Drug-Induced Lupus**","subject":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","page_title":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","episode":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","section_path":["LM_OSRHM 30046f2986ee8098921dc4e04b63ee22"],"source_doc_id":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","source_page":null,"source_anchor":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22-141","focus_area":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","tags":["usmle-step2","core","diagnosis","treatment"]}
{"chunk_type":"transcript_chunk","text":"- **Culprit Drugs:** Hydralazine, Procainamide, Isoniazid, Quinidine. (\"SHIPP-E\" mnemonic).\n- **Antibody:** â˜… **Anti-Histone Antibody** (>95%).\n- **Difference:** ì‹ ì¥(Kidney)ê³¼ ë‡Œ(CNS) ì¹¨ë²”ì€ ë“œë¬¾. ì•½ ëŠìœ¼ë©´ ì¢‹ì•„ì§.\n- **Next Best Step:** Stop the offending drug.\n---\n# 4. Antiphospholipid Syndrome (APS) ğŸ©¸ğŸ¤°\n*Clots & Miscarriages*\n### ğŸšª **Clinical Vignette**\nì Šì€ ì—¬ì„± í™˜ìê°€ **ë°˜ë³µì ì¸ ìœ ì‚°(Recurrent Miscarriages)** í˜¹ì€ ì„¤ëª…ë˜ì§€ ì•ŠëŠ” **í˜ˆì „(DVT/PE/Stroke)** ë³‘ë ¥ì´ ìˆìŒ. PTTê°€ ì—°ì¥ë˜ì–´ ìˆëŠ”ë°(Paradoxical), í˜ˆì „ì´ ìƒê¹€.\n### âš¡ **Diagnostic Criteria**\n1. **Clinical:**\n    - Vascular Thrombosis (Arterial OR Venous).\n    - Pregnancy Morbidity\n        - 3+ unexplained losses <10w\n        - OR 1+ loss >10w\n        - OR severe preeclampsia/placental insufficiency).\n2. **Labs (CONSISTENT: Must be positive 2 times, 12 weeks apart):**\n    - **Lupus Anticoagulant** (False elevation of PTT).\n    - **Anticardiolipin Antibody** (Can cause False Positive VDRL/Syphilis test).\n    - **Anti-beta2-glycoprotein I.**\n### ğŸ’Š **Treatment**\n- **Non-Pregnant:** Warfarin (INR 2-3).\n- **Pregnant:** â˜… **LMWH (Low Molecular Weight Heparin) + Low Dose Aspirin**.\n    - *Note:* Warfarinì€ íƒœì•„ ê¸°í˜•(Teratogenic) ìœ ë°œí•˜ë¯€ë¡œ ì„ì‹  ì¤‘ ê¸ˆê¸°!\n---\n# 5. Mixed Connective Tissue Disease (MCTD) ğŸ§¤ğŸ”—\n*The \"Overlap\" Syndrome*\n### ğŸšª **Doorway Thought**\ní™˜ìê°€ ì™”ëŠ”ë° SLE ê°™ê¸°ë„ í•˜ê³ , Scleroderma(í”¼ë¶€ ê²½í™”) ê°™ê¸°ë„ í•˜ê³ , Polymyositis(ê·¼ìœ¡í†µ) ê°™ê¸°ë„ í•¨. ì†ì´ í‰í‰ ë¶€ì–´ìˆìŒ (**Puffy Hands / Sausage Digits**). ê·¸ë¦¬ê³  ì‹¬í•œ **Raynaud's Phenomenon**ì´ ìˆìŒ.\n### ğŸ§ª **The Golden Key**\n- **Anti-U1-RNP Antibody** (High Titer).\n- ì´ í•­ì²´ê°€ ì–‘ì„±ì´ë©´ì„œ SLE, Systemic Sclerosis, Polymyositisì˜ íŠ¹ì§•ì´ ì„ì—¬ ìˆìœ¼ë©´ MCTDë¡œ ì§„ë‹¨.\n---","subject":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","page_title":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","episode":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","section_path":["LM_OSRHM 30046f2986ee8098921dc4e04b63ee22"],"source_doc_id":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","source_page":null,"source_anchor":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22-161","focus_area":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","tags":["usmle-step2","core","treatment","mnemonic"]}
{"chunk_type":"recap_summary","text":"# ğŸ”¥ Rapid Fire Recap: Treatments & Side Effects\n| **Disease** | **Critical Drug** | **Major Side Effect / Note** |\n| --- | --- | --- |\n| **RA** | **Methotrexate** | Liver tox, Pulmonary fibrosis, **Marrow suppression**. Give **Folate**! |\n| **SLE (General)** | **Hydroxychloroquine** | **Retinopathy** (Eye toxicity). Annual Eye Exam í•„ìˆ˜! |\n| **SLE (Nephritis)** | Cyclophosphamide | Hemorrhagic cystitis (ë°©ê´‘ì—¼), Infertility. |\n| **Drug-Induced Lupus** | (Stop Drug) | Anti-Histone Ab Positive. |\n| **APS (Pregnant)** | **LMWH + Aspirin** | Warfarin is contraindicated. |\n| **RA Flare** | Prednisone | Osteoporosis, Hyperglycemia, Cataracts. |\n1. ê³ í˜ˆì•• ì•½ ë¨¹ë˜ í™˜ìê°€ ê´€ì ˆì´ ì•„íŒŒìš”\n    1. anti-histone ab? DILI. stop the drugs. Hydralazine\n2. ì†ê°€ë½ë¶€ì—ˆê³  Raynaudë„ ìˆê³  malar rashë„ ìˆê³  ê´€ì ˆí†µë„ ìˆê³ ? ì• ë§¤í•œ ì„ ë¬¼ì„¸íŠ¸\n    1. anti U1 RNPê²€ì‚¬! MCTD\n3. ì„ì‹ ì—¬ì„± ê³ í˜ˆì••, ë‹¨ë°±ë‡¨, ë³´ì²´ decreased\n    1. Lupus flare\n4. RAì˜¤ë˜ ì•“ì•˜ë˜ í™˜ìì—ì„œ ê°€ìš´ë° ì†ê°€ë½ ì†í†± ë”¸ê¹í–ˆë”ë‹ˆ ì—„ì§€ì™€ ê²€ì§€ê°€ ì›€ì°”\n    1. Hoffman sign â†’ UMN lesion, cervical myelopathy\n5. RAì˜¤ë˜ ì•“ì•˜ë˜ í™˜ìì—ì„œ ê³„ì† ê°ì—¼ì´ ìƒê¸°ê³  ì™¼ìª½ë°°ê°€ ë¶ˆëŸ¬ì˜¤ë¦„(splenomegaly). í”¼ê²€ì‚¬ì—ì„œ í™•ì¸í•´ì•¼í•  ìˆ«ì\n    1. ANC<2000\n6. ì–´ë–¤ ë¥˜ë§ˆ ì•½ì´ ë¨¹ì€ì§€ 5ë…„í›„ë¶€í„° ì•ˆê³¼ê²€ì§„ ë§¤ë…„í•´ì•¼í•˜ëŠ”ì§€?\n    1. Hydroxychloroquine\n7. Lupusí™˜ìì—ì„œ ë‹¨ë°±ë‡¨ Next Step?\n    1. Renal biopsy\n---\n- **Septic Arthritis vs RA Flare:** WBC > 50,000 in joint fluid = **Septic**. (Medical Emergency! Antibiotics & Drainage). RA flareëŠ” ë³´í†µ 2,000 ~ 50,000 ì‚¬ì´.\n- **Lupus Nephritis:** ì†Œë³€ ê²€ì‚¬ ì´ìƒí•˜ë©´ ë¬´ì¡°ê±´ **Biopsy**. ì¶”ì¸¡ìœ¼ë¡œ ì¹˜ë£Œí•˜ì§€ ë§ ê²ƒ.\n- **RA Cervical Spine:** ìˆ˜ìˆ  ì „ ëª© ì—‘ìŠ¤ë ˆì´ ì•ˆ ì°ì–´ì„œ í™˜ì ë§ˆë¹„ì‹œí‚¤ë©´ ì‹œí—˜ ë–¨ì–´ì§(ê·¸ë¦¬ê³  í™˜ìëŠ” ë¶ˆí–‰í•´ì§). ğŸ’€\n### Overview: Systemic Autoimmune Disorders Part 2 (TL;DR)\nì´ë²ˆ ì—í”¼ì†Œë“œëŠ” ë¥˜ë§ˆí‹°ìŠ¤í•™(Rheumatology)ì˜ ê±°ëŒ€í•œ ë‘ ì‚°ë§¥ì¸ **ì²™ì¶”ê´€ì ˆë³‘ì¦(Spondyloarthropathies)**ê³¼ **ê²°í•©ì¡°ì§ì§ˆí™˜(Connective Tissue Diseases)**ì„ ë‹¤ë£¹ë‹ˆë‹¤. USMLE Step 2 CK ë° ì„ìƒì—ì„œ ìƒëª…ì„ ìœ„í˜‘í•˜ëŠ” í•©ë³‘ì¦(Renal crisis ë“±)ì„ ë†“ì¹˜ì§€ ì•Šê¸° ìœ„í•œ íŒ¨í„´ ì¸ì‹(Pattern Recognition)ì— ì§‘ì¤‘í•©ë‹ˆë‹¤.\n- **Group 1: Seronegative Spondyloarthropathies (SpA)**\n    - íŠ¹ì§•: RF Negative, HLA-B27 ì—°ê´€, ì²™ì¶”/enthesitis ì¹¨ë²”.\n    - ì§ˆí™˜: ê°•ì§ì„± ì²™ì¶”ì—¼(AS), ë°˜ì‘ì„± ê´€ì ˆì—¼(ReA), ê±´ì„  ê´€ì ˆì—¼(PsA).\n- **Group 2: Connective Tissue Heavy Hitters**\n    - ì§ˆí™˜: ì‡¼ê·¸ë Œ ì¦í›„êµ°(Sjogren's), ì „ì‹  ê²½í™”ì¦(Scleroderma - Limited vs Diffuse), ë ˆì´ë…¸ í˜„ìƒ(Raynaud's).\n---","subject":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","page_title":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","episode":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","section_path":["LM_OSRHM 30046f2986ee8098921dc4e04b63ee22"],"source_doc_id":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","source_page":null,"source_anchor":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22-179","focus_area":"LM_OSRHM 30046f2986ee8098921dc4e04b63ee22","tags":["usmle-step2","core","recap","diagnosis","treatment"]}
